<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36984505</article-id><article-id pub-id-type="pmc">10056452</article-id><article-id pub-id-type="doi">10.3390/medicina59030504</article-id><article-id pub-id-type="publisher-id">medicina-59-00504</article-id><article-categories><subj-group subj-group-type="heading"><subject>Opinion</subject></subj-group></article-categories><title-group><article-title>Controlling the Impact of <italic toggle="yes">Helicobacter pylori</italic>-Related Hyperhomocysteinemia on Neurodegeneration</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kountouras</surname><given-names>Jannis</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="c1-medicina-59-00504" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0396-5081</contrib-id><name><surname>Doulberis</surname><given-names>Michael</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="af2-medicina-59-00504" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3563-4973</contrib-id><name><surname>Papaefthymiou</surname><given-names>Apostolis</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="af3-medicina-59-00504" ref-type="aff">3</xref><xref rid="af4-medicina-59-00504" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9232-4042</contrib-id><name><surname>Polyzos</surname><given-names>Stergios A.</given-names></name><xref rid="af4-medicina-59-00504" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Zavos</surname><given-names>Christos</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3045-720X</contrib-id><name><surname>Kazakos</surname><given-names>Evangelos</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="af5-medicina-59-00504" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Arapoglou</surname><given-names>Stergios</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="af6-medicina-59-00504" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Kyrailidi</surname><given-names>Foteini</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mouratidou</surname><given-names>Maria C.</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6601-5163</contrib-id><name><surname>Boziki</surname><given-names>Marina</given-names></name><xref rid="af7-medicina-59-00504" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3698-9135</contrib-id><name><surname>Vardaka</surname><given-names>Elisabeth</given-names></name><xref rid="af1-medicina-59-00504" ref-type="aff">1</xref><xref rid="af8-medicina-59-00504" ref-type="aff">8</xref></contrib></contrib-group><aff id="af1-medicina-59-00504"><label>1</label>Second Medical Clinic, School of Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Macedonia, Greece</aff><aff id="af2-medicina-59-00504"><label>2</label>Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, 5001 Aarau, Switzerland</aff><aff id="af3-medicina-59-00504"><label>3</label>Pancreaticobiliary Medicine Unit, University College London Hospitals (UCLH), London W1W 6DN, UK</aff><aff id="af4-medicina-59-00504"><label>4</label>First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Macedonia, Greece</aff><aff id="af5-medicina-59-00504"><label>5</label>School of Healthcare Sciences, Midwifery Department, University of West Macedonia, Koila, 50100 Kozani, Macedonia, Greece</aff><aff id="af6-medicina-59-00504"><label>6</label>Fifth Surgical Department, Medical School, Ippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Macedonia, Greece</aff><aff id="af7-medicina-59-00504"><label>7</label>2nd Neurology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, 54124 Thessaloniki, Macedonia, Greece</aff><aff id="af8-medicina-59-00504"><label>8</label>Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Alexander Campus, 57400 Thessaloniki, Macedonia, Greece</aff><author-notes><corresp id="c1-medicina-59-00504"><label>*</label>Correspondence: <email>jannis@auth.gr</email>; Tel.: +30-2310-438714; Fax: +30-2310-992794</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>59</volume><issue>3</issue><elocation-id>504</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2022</year></date><date date-type="rev-recd"><day>27</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic toggle="yes">Helicobacter pylori</italic> infection consists a high global burden affecting more than 50% of the world&#x02019;s population. It is implicated, beyond substantiated local gastric pathologies, i.e., peptic ulcers and gastric cancer, in the pathophysiology of several neurodegenerative disorders, mainly by inducing hyperhomocysteinemia-related brain cortical thinning (BCT). BCT has been advocated as a possible biomarker associated with neurodegenerative central nervous system disorders such as Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, multiple sclerosis, and/or glaucoma, termed as &#x0201c;ocular Alzheimer&#x02019;s disease&#x0201d;. According to the infection hypothesis in relation to neurodegeneration, <italic toggle="yes">Helicobacter pylori</italic> as non-commensal gut microbiome has been advocated as trigger and/or mediator of neurodegenerative diseases, such as the development of Alzheimer&#x02019;s disease. Among others, <italic toggle="yes">Helicobacter pylori</italic>-related inflammatory mediators, defensins, autophagy, vitamin D, dietary factors, role of probiotics, and some pathogenetic considerations including relevant involved genes are discussed within this opinion article. In conclusion, by controlling the impact of <italic toggle="yes">Helicobacter pylori</italic>-related hyperhomocysteinemia on neurodegenerative disorders might offer benefits, and additional research is warranted to clarify this crucial topic currently representing a major worldwide burden.</p></abstract><kwd-group><kwd><italic toggle="yes">H. pylori</italic></kwd><kwd>hyperhomocysteinemia</kwd><kwd>brain cortical thinning</kwd><kwd>neurodegeneration</kwd><kwd>Alzheimer&#x02019;s disease</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-59-00504"><title>1. Introduction</title><p>Recent data indicate the implications of microorganisms in the pathophysiology of neurodegeneration [<xref rid="B1-medicina-59-00504" ref-type="bibr">1</xref>,<xref rid="B2-medicina-59-00504" ref-type="bibr">2</xref>]. For instance, according to the Alzheimer&#x02019;s disease (AD) pathogen theory, microorganisms operate as triggers, in conjunction with genetic variables, in starting the accumulation and/or processing of amyloid-&#x003b2; (A&#x003b2;), hyperphosphorylated tau proteins, and inflammation in the brains of AD [<xref rid="B3-medicina-59-00504" ref-type="bibr">3</xref>]. Furthermore, brain cortical thinning (BCT), a hallmark feature mainly of brain aging, is linked with cognitive decline [<xref rid="B4-medicina-59-00504" ref-type="bibr">4</xref>] and memory function disturbances [<xref rid="B5-medicina-59-00504" ref-type="bibr">5</xref>]. BCT has been identified in many neurodegenerative disorders including AD [<xref rid="B6-medicina-59-00504" ref-type="bibr">6</xref>], Parkinson&#x02019;s disease (PD) [<xref rid="B7-medicina-59-00504" ref-type="bibr">7</xref>], multiple sclerosis [<xref rid="B8-medicina-59-00504" ref-type="bibr">8</xref>], or schizophrenia [<xref rid="B9-medicina-59-00504" ref-type="bibr">9</xref>]. It is used as a biomarker of cognitive performance [<xref rid="B10-medicina-59-00504" ref-type="bibr">10</xref>] to recognize mild cognitive-impairment subtypes [<xref rid="B11-medicina-59-00504" ref-type="bibr">11</xref>]; to follow the clinical progression of disorders such as PD [<xref rid="B7-medicina-59-00504" ref-type="bibr">7</xref>] or the progression of mild cognitive impairment to AD [<xref rid="B10-medicina-59-00504" ref-type="bibr">10</xref>]; and to evaluate the effectiveness of interventional and rehabilitation procedures targeting improvements in sensory, motor, and cognitive functions [<xref rid="B11-medicina-59-00504" ref-type="bibr">11</xref>].</p><p>Specifically, BCT, among other radiological MRI measurements, has been advocated as a possible biomarker associated with neurodegeneration either for primary neurodegenerative central nervous system (CNS) disorders such as AD [<xref rid="B12-medicina-59-00504" ref-type="bibr">12</xref>] and/or PD [<xref rid="B13-medicina-59-00504" ref-type="bibr">13</xref>] or other CNS disorders with a neurodegenerative pathological component, such as multiple sclerosis [<xref rid="B13-medicina-59-00504" ref-type="bibr">13</xref>] and/or cardio-cerebrovascular-related dementia [<xref rid="B14-medicina-59-00504" ref-type="bibr">14</xref>,<xref rid="B15-medicina-59-00504" ref-type="bibr">15</xref>]. There are currently no diagnostic criteria for BCT; rather, longitudinal studies in the field provide estimates of normative rates in CNS pathology compared to age-related cortical thinning [<xref rid="B16-medicina-59-00504" ref-type="bibr">16</xref>,<xref rid="B17-medicina-59-00504" ref-type="bibr">17</xref>]. T1-weighted three-dimensional structural MRI scans are frequently used for this purpose, although advanced neuroimaging methodologies are continuously evolving [<xref rid="B16-medicina-59-00504" ref-type="bibr">16</xref>]. </p><p>According to the infection hypothesis in relation to neurodegeneration, microorganisms have been advocated as triggers and/or mediators of neurodegenerative diseases such as the development of AD [<xref rid="B18-medicina-59-00504" ref-type="bibr">18</xref>]. The infection hypothesis of AD proposes that chronic infection with viral, bacterial, and/or fungal pathogens might be a trigger for AD onset during aging&#x02014;probably via inflammatory processes&#x02014;the risk of which seems predominantly high in apolipoprotein E (APOE) &#x003b5;44 allele carriers. More specifically, proposed pathogens include latent neurotropic viruses (<italic toggle="yes">Herpes simplex</italic> virus type-1 and type-2; <italic toggle="yes">Human herpes</italic>- virus 4, 5, 6, and 7), gastrointestinal bacteria (<italic toggle="yes">Helicobacter pylori</italic>), periodontal bacteria (e.g., <italic toggle="yes">Porphyromonas gingivalis</italic>), pulmonary bacteria (e.g., <italic toggle="yes">Chlamydophila pneumoniae</italic>), spirochetes (e.g., <italic toggle="yes">Borrelia burgdorferi</italic>), and other infectious pathogens [<xref rid="B18-medicina-59-00504" ref-type="bibr">18</xref>,<xref rid="B19-medicina-59-00504" ref-type="bibr">19</xref>,<xref rid="B20-medicina-59-00504" ref-type="bibr">20</xref>,<xref rid="B21-medicina-59-00504" ref-type="bibr">21</xref>]. Over the last years, many detailed reviews have summarized the evidence about <italic toggle="yes">herpes simplex virus type</italic>-1, <italic toggle="yes">Chlamydophila pneumoniae</italic>, <italic toggle="yes">Helicobacter pylori</italic>, <italic toggle="yes">Porphyromonas gingivalis,</italic> and other oral infectious agents with the pathophysiology of AD [<xref rid="B19-medicina-59-00504" ref-type="bibr">19</xref>]. </p><p>In this regard, <italic toggle="yes">Helicobacter pylori</italic> (<italic toggle="yes">H. pylori</italic>) infection consists one of the most common chronic infections since it affects more than 50% of the world population [<xref rid="B22-medicina-59-00504" ref-type="bibr">22</xref>]. Emerging evidence supports its involvement in the pathophysiology of many neurodegenerative disorders [<xref rid="B21-medicina-59-00504" ref-type="bibr">21</xref>,<xref rid="B23-medicina-59-00504" ref-type="bibr">23</xref>,<xref rid="B24-medicina-59-00504" ref-type="bibr">24</xref>,<xref rid="B25-medicina-59-00504" ref-type="bibr">25</xref>,<xref rid="B26-medicina-59-00504" ref-type="bibr">26</xref>,<xref rid="B27-medicina-59-00504" ref-type="bibr">27</xref>,<xref rid="B28-medicina-59-00504" ref-type="bibr">28</xref>]. Specifically, found in gastric mucosa of &#x02265;50% of humans worldwide, <italic toggle="yes">H. pylori</italic> can infect children, becoming chronic during adulthood if untreated; in most patients, <italic toggle="yes">H. pylori</italic> infections are acquired in childhood and, if untreated, persist throughout life [<xref rid="B29-medicina-59-00504" ref-type="bibr">29</xref>], causing the chronic inflammatory process of the stomach lining and leading to many gastric as well as other upper and lower gastrointestinal and extra-gastrointestinal pathologies [<xref rid="B30-medicina-59-00504" ref-type="bibr">30</xref>,<xref rid="B31-medicina-59-00504" ref-type="bibr">31</xref>,<xref rid="B32-medicina-59-00504" ref-type="bibr">32</xref>,<xref rid="B33-medicina-59-00504" ref-type="bibr">33</xref>]. Therefore, epidemiological estimates of <italic toggle="yes">H. pylori</italic> prevalence refer to the untreated chronic <italic toggle="yes">H. pylori</italic> infection in adulthood. In this regard, chromic <italic toggle="yes">H. pylori</italic> infection is very common, with an assessed global mean prevalence of 58% (varies from 39.9% to 91.7%), partly due to immigrants coming from countries with a high prevalence of <italic toggle="yes">H. pylori</italic> infection [<xref rid="B30-medicina-59-00504" ref-type="bibr">30</xref>,<xref rid="B34-medicina-59-00504" ref-type="bibr">34</xref>,<xref rid="B35-medicina-59-00504" ref-type="bibr">35</xref>]; it accounts of about 4.4 billion of the world&#x02019;s <italic toggle="yes">H. pylori</italic> chronically infected individuals [<xref rid="B36-medicina-59-00504" ref-type="bibr">36</xref>].</p><p>Despite the strong innate and adaptive immune responses, <italic toggle="yes">H. pylori</italic> exhibits long-term survival in the gastric mucosa. Its survival is intensely influenced by the ability of this bacterium to escape, disrupt, and manipulate the host immune responses. <italic toggle="yes">H. pylori</italic> employs several mechanisms to evade innate and adaptive immune systems&#x02019; immunity, allowing the bacterium to establish chronic infection [<xref rid="B37-medicina-59-00504" ref-type="bibr">37</xref>]. <italic toggle="yes">H. pylori</italic>, by perturbing the gastric mucosa immune equilibrium, induces a microenvironment that favors gastric oncogenesis and evasion of immune surveillance [<xref rid="B38-medicina-59-00504" ref-type="bibr">38</xref>]. This bacterium can escape from being recognized by innate immune receptors through changing its surface molecules. <italic toggle="yes">H. pylori</italic> can also block other innate recognition receptors by constraining downstream signaling pathways. Specifically, to the evasion of innate immune system mechanisms belong, among others, the following: neutralization of reactive oxygen and nitrogen species released by macrophages, alteration of cytokine secretion and the maturation of dendritic cells, and more passive systems such as the variability and the uniquely low immunogenicity of <italic toggle="yes">H. pylori</italic> lipopolysaccharide (LPS) [<xref rid="B39-medicina-59-00504" ref-type="bibr">39</xref>]. Moreover, the expression of Lewis antigens in the LPS of <italic toggle="yes">H. pylori</italic> provides the bacterium with the ability to mimic host antigens and thus conceal itself from the immune system. <italic toggle="yes">H. pylori</italic> is also able to escape from the host adaptive immunity by modifying the function of the T lymphocytes.&#x000a0;In this respect, <italic toggle="yes">H. pylori</italic> evasion from destruction by both the innate and adaptive immune responses may contribute to AD pathology [<xref rid="B40-medicina-59-00504" ref-type="bibr">40</xref>].</p><p>It is important to note that diverse issues involved in the failure to eradicate <italic toggle="yes">H. pylori</italic> include, among others, <italic toggle="yes">H. pylori</italic> genotypes with high pathogenicity, the occurrence of point mutations, increased <italic toggle="yes">H. pylori</italic> burden, immunosuppressant characteristics, acidic gastric pH, intracellular occurrence of <italic toggle="yes">H. pylori</italic>, and/or biofilm creation linked with efflux pumps (transporters removing antibiotics from the cellular inner) [<xref rid="B41-medicina-59-00504" ref-type="bibr">41</xref>]. <italic toggle="yes">H. pylori</italic> exhibits the ability to form biofilm in the stomach, which significantly decreases sensitivity to antibiotics and other antimicrobial agents and represents an independent mechanism that may be involved in the development and/or intensification of the antibiotic resistance. <italic toggle="yes">H. pylori</italic> biofilm appears to be a main reason of failure to eliminate infections triggered by <italic toggle="yes">H. pylori</italic>; antimicrobial agents are not capable of penetrating and destroying the biofilm; and <italic toggle="yes">H. pylori</italic> mutations resistant to antibiotics such as clarithromycin are commonly created in biofilms. Therefore, affecting the <italic toggle="yes">H. pylori</italic> biofilm-related pathologies can offer an efficient approach to avoid failures of <italic toggle="yes">H. pylori</italic> therapeutic regimens [<xref rid="B41-medicina-59-00504" ref-type="bibr">41</xref>]. In this respect, exposure to key components of the innate immune system antimicrobial peptides, such as high human &#x003b2;-defensins (h&#x003b2;Ds) 1&#x02013;4 concentrations, significantly inhibits the capability for biofilm formation by <italic toggle="yes">H. pylori,</italic> a finding principally attributed to antibacterial action of h&#x003b2;Ds [<xref rid="B42-medicina-59-00504" ref-type="bibr">42</xref>]. Nevertheless, if <italic toggle="yes">H. pylori</italic> may access the brain, it could trigger the development and progression of neurodegenerative disorders, possibly by inducing defensin abnormal expression [<xref rid="B43-medicina-59-00504" ref-type="bibr">43</xref>]. </p><p><italic toggle="yes">H. pylori</italic> also induces an intracellular niche that protects the bacterium from antibiotic eradication therapy, allowing persistence and recolonization. This intracellular niche may also contribute to bacterial evasion of the host immune responses [<xref rid="B41-medicina-59-00504" ref-type="bibr">41</xref>]. In this regard, for instance, VDP, a direct vitamin D metabolite, possesses a <italic toggle="yes">H. pylori</italic>-specific antimicrobial ability through h&#x003b2;Ds induction from infected macrophages, thus creating a promising therapeutic potential [<xref rid="B41-medicina-59-00504" ref-type="bibr">41</xref>]. Notably, addition of vitamin D3 to the conventional clarithromycin-based triple therapeutic approach also offers a significant eradication rate of <italic toggle="yes">H. pylori</italic> infection. </p><p>Apart from defensins, another key component of the innate immune system, namely human cathelicidin LL-37, is able to prevent <italic toggle="yes">H. pylori</italic> biofilm creation by inhibiting <italic toggle="yes">H. pylori</italic> adhesion, downregulating biofilm-related genes, suppressing quorum-sensing pathways, degrading the biofilm matrix, and suppressing the biofilm-residing cells [<xref rid="B44-medicina-59-00504" ref-type="bibr">44</xref>]. </p><p>Autophagy is involved in <italic toggle="yes">H. pylori</italic>-induced gastritis, and chronic <italic toggle="yes">H. pylori</italic> infection promotes gastric malignancy growth and progress by considerably weakening autophagy; although autophagy offers an anti-carcinogenic effect in normal tissues, the occurrence of an excess of altering triggers, such as <italic toggle="yes">H. pylori</italic> infection, prevents its activity, thereby promoting cancer development [<xref rid="B41-medicina-59-00504" ref-type="bibr">41</xref>]. Interestingly, circulating monocytes (infected with <italic toggle="yes">H. pylori</italic> due to defective autophagy) through a disrupted blood&#x02013;brain barrier (BBB) may trigger neurodegeneration [<xref rid="B45-medicina-59-00504" ref-type="bibr">45</xref>]. The clarification of the interaction among <italic toggle="yes">H. pylori</italic> and autophagic process has driven investigators to examine the effect of the regulators of the autophagic process in order to control <italic toggle="yes">H. pylori</italic> infection in an effort to improve the rising antibiotic resistance. However, future research is warranted to elucidate in depth the above-mentioned considerations. </p><p>Recurrence/reinfection of <italic toggle="yes">H. pylori</italic> infection can occur, and it can be categorized into two distinct mechanisms: recrudescence and reinfection [<xref rid="B46-medicina-59-00504" ref-type="bibr">46</xref>]. The recrudescence is the reappearance of the original strain following initial eradication; it is considered to be a failure of eradication. The reinfection is infected with a new strain after initial eradication. The identification of the <italic toggle="yes">H. pylori</italic> strain needs the application of certain molecular fingerprinting techniques. These techniques are very complex procedures and demand high personnel and facilities resources. Therefore, currently, it cannot be widely introduced in clinical and scientific investigation. Some investigators consider that the recurrence of <italic toggle="yes">H. pylori</italic> infection less than 1 year after eradication is categorized as recrudescence but reinfection if it was more than 1 year [<xref rid="B47-medicina-59-00504" ref-type="bibr">47</xref>,<xref rid="B48-medicina-59-00504" ref-type="bibr">48</xref>]. Other investigators consider that the change of <italic toggle="yes">H pylori</italic> from negative to positive at 1 year following initial eradication might be caused by recurrence or reinfection, and reinfection is the principal cause of recurrence at 3 years after successful eradication [<xref rid="B49-medicina-59-00504" ref-type="bibr">49</xref>]. A relative review and meta-analysis showed that the global annual recurrence, reinfection, and recrudescence rates of <italic toggle="yes">H. pylori</italic> were 4.3%, 3.1%, and 2.2%, respectively [<xref rid="B50-medicina-59-00504" ref-type="bibr">50</xref>]. Risk factors of <italic toggle="yes">H. pylori</italic> reinfection include, among others, dental-plaque-related periodontitis, which is a multifactorial inflammatory disorder mediated by the host immune response to dental plaque [<xref rid="B51-medicina-59-00504" ref-type="bibr">51</xref>,<xref rid="B52-medicina-59-00504" ref-type="bibr">52</xref>]. Periodontitis is a risk factor for development of neurodegenerative disorders including AD, PD, or multiple sclerosis [<xref rid="B53-medicina-59-00504" ref-type="bibr">53</xref>,<xref rid="B54-medicina-59-00504" ref-type="bibr">54</xref>].</p><p>A large number of published studies cover <italic toggle="yes">H. pylori</italic>-preventing strategies, including dietary regimens. In general, dietary intervention to prevent <italic toggle="yes">H. pylori</italic>-related severe pathologies might be ideal because it carries no risk of bacterial resistance, safety, and rejuvenating action of atrophic gastritis. A few recent examples are the following: </p><p>Soy product consumption significantly reduced the incidence of gastric cancer [<xref rid="B55-medicina-59-00504" ref-type="bibr">55</xref>]. This could be attributed to the isoflavones (e.g., genistein, daidzein, and glycitein) that are abundant in soy products. In particular, genistein inhibits the growth of <italic toggle="yes">H. pylori</italic> and the activity of nuclear factor (NF)-&#x003ba;B, which is associated with gastrointestinal tract tumorigenesis [<xref rid="B55-medicina-59-00504" ref-type="bibr">55</xref>].</p><p>Cranberry supplementation appears to improve the success of eradication of <italic toggle="yes">H. pylori</italic> infection, which represents the major cause of peptic ulcer disease and gastric cancer [<xref rid="B56-medicina-59-00504" ref-type="bibr">56</xref>].</p><p>Vitamins A, C, D, E, B6, B9, and B12 as well as key minerals such as zinc, iron, copper, nickel, and selenium may be involved in <italic toggle="yes">H. pylori</italic> infection and eradication. The antioxidant activity of vitamins can reduce oxidative stress and further suppress <italic toggle="yes">H. pylori</italic>-induced inflammation. Moreover, in vitro studies demonstrated promising anti-<italic toggle="yes">H. pylori</italic> mechanisms for vitamin administration in a dose-dependent manner. Antioxidants including certain vitamins may exhibit a preventative and therapeutic potential against AD, thereby offering insights into the association between oxidative stress and neurodegenerative disorders [<xref rid="B57-medicina-59-00504" ref-type="bibr">57</xref>].</p><p>The administration of probiotics seems to reduce <italic toggle="yes">H. pylori</italic> adhesion to gastric epithelial cells and prevent <italic toggle="yes">H. pylori</italic> colonization, particularly in children, or reinfection with <italic toggle="yes">H. pylori</italic> in high-risk adult patients [<xref rid="B58-medicina-59-00504" ref-type="bibr">58</xref>]. In this respect, recent data indicate that probiotic supplementation also exhibits a highly significant effect on cognitive function in patients with both cognitive impairment and AD [<xref rid="B59-medicina-59-00504" ref-type="bibr">59</xref>].</p><p>Maintaining good hygiene is effective strategy in preventing <italic toggle="yes">H. pylori</italic> infection [<xref rid="B60-medicina-59-00504" ref-type="bibr">60</xref>]. Likewise, maintaining good hygiene (oral) is an effective strategy in improving the clinical condition of patients with AD [<xref rid="B61-medicina-59-00504" ref-type="bibr">61</xref>].</p><p>However, such <italic toggle="yes">H. pylori</italic>-preventive strategies warrant further evaluation.</p><p>Interestingly, <italic toggle="yes">H. pylori</italic> is also related to metabolic syndrome (MetS)-systemic pathologies such as cardio-cerebrovascular and neurodegenerative diseases, the end outcomes of MetS [<xref rid="B22-medicina-59-00504" ref-type="bibr">22</xref>,<xref rid="B62-medicina-59-00504" ref-type="bibr">62</xref>].</p><p>In this respect, by introducing gastric mucosa histology representing the practical diagnostic gold standard for active burden of <italic toggle="yes">H. pylori</italic> infection, this infection, as in the case of the patients with neurodegenerative disorders, is also connected with BCT even in cognitively normal people. This connection persists despite further adjustment for MetS risk factors, thereby indicating that the active burden of <italic toggle="yes">H. pylori</italic> infection may contribute to neurodegeneration in cognitively normal people [<xref rid="B63-medicina-59-00504" ref-type="bibr">63</xref>]. In contrast, <italic toggle="yes">H. pylori</italic> eradication regimens may ameliorate and/or prevent both local and systemic chronic <italic toggle="yes">H. pylori</italic> infection-related disorders. For instance, in a topical setting, <italic toggle="yes">H. pylori</italic> eradication seems to reduce and/or prevent autoimmune gastritis as indicated by improvement of gastric atrophy on follow-up, mucosa-associated lymphoid tissue lymphoma, gastric adenocarcinoma, as well as metachronous gastric cancer and preneoplastic lesions including atrophic gastritis and intestinal metaplasia [<xref rid="B64-medicina-59-00504" ref-type="bibr">64</xref>,<xref rid="B65-medicina-59-00504" ref-type="bibr">65</xref>]. In a systemic setting, <italic toggle="yes">H. pylori</italic> eradication may exert a positive effect on AD manifestations at 5-year survival endpoints [<xref rid="B63-medicina-59-00504" ref-type="bibr">63</xref>]. Likewise, eradication of this bacterium could constrain the progression of clinically isolated syndrome to the development of multiple sclerosis [<xref rid="B25-medicina-59-00504" ref-type="bibr">25</xref>]. Moreover, <italic toggle="yes">H. pylori</italic> eradication results in significant clinical improvement in the symptoms and better PD patient outcomes [<xref rid="B66-medicina-59-00504" ref-type="bibr">66</xref>,<xref rid="B67-medicina-59-00504" ref-type="bibr">67</xref>,<xref rid="B68-medicina-59-00504" ref-type="bibr">68</xref>]. It is important to note that abnormal BCT may contribute to cognitive decline in patients with PD [<xref rid="B69-medicina-59-00504" ref-type="bibr">69</xref>,<xref rid="B70-medicina-59-00504" ref-type="bibr">70</xref>]. Furthermore, regarding glaucoma (defined as &#x0201c;ocular&#x0201d; AD), we reported a 2-year beneficial effect of <italic toggle="yes">H. pylori</italic> eradication on glaucoma progression, suggesting a possible causal link between this bacterium and glaucoma [<xref rid="B45-medicina-59-00504" ref-type="bibr">45</xref>,<xref rid="B71-medicina-59-00504" ref-type="bibr">71</xref>]. BCT may also contribute to the severity and progression of glaucoma, thereby serving as a novel marker for assessing the severity of glaucoma [<xref rid="B72-medicina-59-00504" ref-type="bibr">72</xref>,<xref rid="B73-medicina-59-00504" ref-type="bibr">73</xref>].</p><p>Various <italic toggle="yes">H. pylori</italic>-related potential mechanisms that trigger neurodegeneration include the following: <italic toggle="yes">H. pylori</italic>-induced systemic inflammatory responses; <italic toggle="yes">H. pylori</italic>-induced metabolic dysfunctions; <italic toggle="yes">H. pylori</italic>-related direct brain injury by inducing toxic materials or by attacking the brain via gastrointestinal retrograde axonal transport or oral-nasal olfactory pathways; circulated <italic toggle="yes">H. pylori</italic>-infected monocytes that enter the brain due to disruption of BBB (Trojan horse concept) and induce neurodegeneration; and/or <italic toggle="yes">H. pylori</italic>-related gastrointestinal microbiota dysbiosis that modifies the gut&#x02013;brain axis toward neurodegeneration [<xref rid="B63-medicina-59-00504" ref-type="bibr">63</xref>] (<xref rid="medicina-59-00504-f001" ref-type="fig">Figure 1</xref>). </p><p>More specifically, <italic toggle="yes">H. pylori</italic> infection induces the release of a variety of molecules, such as IFN-&#x003b3;, TNF-&#x003b1;, CRP, and IL-1, IL-6, and IL-10, all of which may promote apoptosis of neural tissue [<xref rid="B74-medicina-59-00504" ref-type="bibr">74</xref>]. Additionally, structural components of <italic toggle="yes">H. pylori</italic> exhibit direct pro-inflammatory properties. For instance, <italic toggle="yes">H. pylori</italic> (2&#x02013;20) peptides expressed by <italic toggle="yes">H. pylori</italic>, together with amyloid-&#x003b2;42, act as a ligand for formyl peptide receptors that play a key role in inflammation and lead to neurodegeneration. <italic toggle="yes">H. pylori</italic> (2&#x02013;20)-mediated signaling results in increase of the vascular endothelial growth factor, a well-described mediator predisposing to vascular and other neurodegenerative dementias [<xref rid="B75-medicina-59-00504" ref-type="bibr">75</xref>]. The direct pro-inflammatory properties of <italic toggle="yes">H. pylori</italic> infection components are also supported by experimental studies, according to which soluble surface fractions of <italic toggle="yes">H. pylori</italic> infection may lead to cognitive impairment by promoting the formation of A&#x003b2;42, thus compromising synaptic integrity and mediating neuronal damage [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>]. Moreover, <italic toggle="yes">H. pylori</italic> infection associated with MetS may contribute to the vascular pathology, a well-described predisposing factor for neurodegenerative disease, by inducing increased plasma homocysteine levels and reduced serum 5-methyltetrahydrofolate and vitamin B-12, thus subsequently promoting endothelial damage. Interestingly, individuals with <italic toggle="yes">H. pylori</italic> infection exhibited cognitive impairment, the degree of which correlated with decreased 5-methyltetrahydrofolate levels [<xref rid="B77-medicina-59-00504" ref-type="bibr">77</xref>]. <italic toggle="yes">H. pylori</italic> infection is also associated with increased tau-hyperphosphorylation, the key component of neurofibrillary tangles in AD [<xref rid="B78-medicina-59-00504" ref-type="bibr">78</xref>]; it induces tau hyperphosphorylation, which is directly linked to the AD-associated neurodegeneration [<xref rid="B79-medicina-59-00504" ref-type="bibr">79</xref>]. Intraperitoneal inoculation of <italic toggle="yes">H. pylori</italic> filtrate in rats provokes spatial learning and memory deficits, abnormal hippocampal dendritic spine maturation, and augmented presenilin-2 and A&#x003b2;42 in the brain&#x02019;s hippocampus and cortex. Furthermore, <italic toggle="yes">H. pylori</italic> filtrate stimulates considerable tau hyperphosphorylation in mouse neuroblastoma N2a [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>]. Since phosphorylation of tau is attenuated by the glycogen synthase kinase 3 inhibitor, this provides preliminary evidence for a beneficiary role of <italic toggle="yes">H. pylori</italic> eradication in AD and the need for verification by large-scale clinical trials [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>]. Furthermore, we recently reviewed potential Galectin (Gal)-3-mediated mechanisms by which <italic toggle="yes">H. pylori</italic> may also promote neurodegeneration [<xref rid="B27-medicina-59-00504" ref-type="bibr">27</xref>]. Gal-3 is a glycan-binding protein implicated in several physiologic and pathological processes including cell signaling, proliferation, and migration as well as the stimulation of immune response. <italic toggle="yes">H. pylori</italic> infection may promote neuroinflammation and neurodegeneration by several Gal-3-dependent pathways [<xref rid="B27-medicina-59-00504" ref-type="bibr">27</xref>,<xref rid="B80-medicina-59-00504" ref-type="bibr">80</xref>,<xref rid="B81-medicina-59-00504" ref-type="bibr">81</xref>]. In addition, <italic toggle="yes">H. pylori</italic>-derived outer membrane vesicles modulate the physiological functions of glial cells and neurons and can worsen AD pathology [<xref rid="B82-medicina-59-00504" ref-type="bibr">82</xref>]. <italic toggle="yes">H. pylori</italic> infection and/or gut microbiota alteration by promoting chronic inflammation, may influence both the occurrence and evolution of AD [<xref rid="B83-medicina-59-00504" ref-type="bibr">83</xref>] (<xref rid="medicina-59-00504-f001" ref-type="fig">Figure 1</xref>). <italic toggle="yes">H. pylori,</italic> by releasing several inflammatory mediators (e.g., cytokines and chemokines induced by <italic toggle="yes">H. pylori</italic> infection), may induce BBB/blood&#x02013;ocular barrier (BOB) breakdown, thereby being involved in the pathogenesis of neuropathies such as AD and glaucoma. TNF-&#x003b1;, induced by <italic toggle="yes">H. pylori</italic> infection, is involved in BBB disruption via a mechanism involving matrix metalloproteinase upregulation [<xref rid="B62-medicina-59-00504" ref-type="bibr">62</xref>]. <italic toggle="yes">H. pylori</italic> VacA cytotoxin promotes intracellular survival of <italic toggle="yes">H. pylori</italic>, and activated monocytes (possibly infected with <italic toggle="yes">H. pylori</italic> due to defective autophagy) might access the brain (Trojan horse theory) via BBB/BOB disruption, thereby triggering the development and progression of neurodegenerative disorders, possibly by inducing additional defensin abnormal expression; when <italic toggle="yes">H. pylori</italic> accesses the brain, it may trigger defensin-related dendritic cells maturation and activation, leading to pro-inflammatory cytokine release by effector T cells, thereby promoting neuronal cell injury and death [<xref rid="B24-medicina-59-00504" ref-type="bibr">24</xref>]. Furthermore, <italic toggle="yes">H. pylori</italic> could further contribute to neurodegenerative disorders&#x02019; pathogenesis by inducing MetS-related platelet&#x02013;leukocyte aggregation, which is proposed to play pathophysiologic roles in AD; producing reactive oxygen species and circulating lipid peroxides implicated in AD pathobiology; and influencing the apoptotic process, a crucial cell death form in AD [<xref rid="B66-medicina-59-00504" ref-type="bibr">66</xref>].</p><p>Therefore, controlling <italic toggle="yes">H. pylori</italic> infection may exhibit beneficial effects on neurodegeneration [<xref rid="B22-medicina-59-00504" ref-type="bibr">22</xref>,<xref rid="B62-medicina-59-00504" ref-type="bibr">62</xref>].</p><p>Additional critical triggers, particularly <italic toggle="yes">H. pylori</italic>-induced hyperhomocysteinemia, may play a crucial role in brain neurodegenerative disorders by provoking BCT in both normal males and females [<xref rid="B84-medicina-59-00504" ref-type="bibr">84</xref>]. Since BCT, identified during the prodromal stages of AD, is a &#x0201c;candidate&#x0201d; biomarker implemented in AD clinical therapy trials, <italic toggle="yes">H. pylori</italic> eradication regimens, by affecting such BCT triggers, may exhibit a positive impact on cortical thickness, thereby signifying a relative protecting role in the development of brain-degenerative pathologies. </p><p>Recently, genetic polymorphisms in genes that have been implicated in AD, a primary neurodegenerative disease and the most common cause of dementia worldwide [<xref rid="B85-medicina-59-00504" ref-type="bibr">85</xref>], include, among others, <italic toggle="yes">ABCA7</italic> [<xref rid="B86-medicina-59-00504" ref-type="bibr">86</xref>], <italic toggle="yes">PICALM</italic> [<xref rid="B87-medicina-59-00504" ref-type="bibr">87</xref>], <italic toggle="yes">CLU</italic> [<xref rid="B88-medicina-59-00504" ref-type="bibr">88</xref>], <italic toggle="yes">SLC24A4/RIN3</italic> [<xref rid="B89-medicina-59-00504" ref-type="bibr">89</xref>], <italic toggle="yes">ECHDC3</italic> [<xref rid="B90-medicina-59-00504" ref-type="bibr">90</xref>], <italic toggle="yes">MTHFR</italic> [<xref rid="B91-medicina-59-00504" ref-type="bibr">91</xref>], as well as in insulin signaling such as <italic toggle="yes">INSR</italic> [<xref rid="B92-medicina-59-00504" ref-type="bibr">92</xref>]. <italic toggle="yes">MTHFR</italic> mutations are associated with homocysteinemia, and increased homocysteine blood levels are considered to be an independent risk factor of cerebrovascular incidents. There are two common polymorphic genetic variants of the <italic toggle="yes">MTHFR</italic> gene that can lead to impaired functioning of the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine, leading to hyperhomocysteinemia, which is a risk factor for dementia owing to an associated BBB dysfunction and subsequent small-vessel disease pathology [<xref rid="B93-medicina-59-00504" ref-type="bibr">93</xref>]. Of note, the C677T polymorphism on the <italic toggle="yes">MTHFR</italic> gene can affect migraine susceptibility, with the resultant migraine being due to the increase in homocysteine levels in the blood [<xref rid="B94-medicina-59-00504" ref-type="bibr">94</xref>]. Mutations in the gene SCIMP, a gene implicated in TLR-dependent activation of microglia, the innate immune system cell of the CNS, also have been recently identified in AD [<xref rid="B95-medicina-59-00504" ref-type="bibr">95</xref>], thus shedding light onto possible mechanisms through which microbes and other infectious agents may affect the CNS in the context of neurodegeneration.</p><p>Specifically, atrophic gastritis due to <italic toggle="yes">H. pylori</italic> infection-related MetS provokes deficiency of both vitamin B12 and folic acid, leading to hyperhomocysteinemia with consequent injury of the vascular endothelium [<xref rid="B96-medicina-59-00504" ref-type="bibr">96</xref>]; <italic toggle="yes">H. pylori</italic>-provoked chronic gastritis leads to defective absorption of vitamin B12 and folate, resulting in methylation by 5-methyl-tetrahydrofolic acid malfunction and, therefore, in hyperhomocysteinemia [<xref rid="B96-medicina-59-00504" ref-type="bibr">96</xref>] (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). More specifically, homocysteine, a sulfur-containing amino acid derived from methionine, is principally metabolized via methionine-synthase in the remethylation cycle, which is dependent on the presence of both vitamin B12 and folate as co-factors. The mechanisms of vitamin B12 malabsorption by <italic toggle="yes">H. pylori</italic> infection that result in hyperhomocysteinemia are unclear, but the following explanations are possible: First, as acid and pepsin are critical for splitting vitamin B12 from food binders and for its subsequent transfer to R binder in the stomach, the diminished acid secretion in <italic toggle="yes">H. pylori</italic>-induced gastritis may lead to a failure in absorption of food-bound vitamin B12. Second, <italic toggle="yes">H. pylori</italic>-induced gastritis could cause a secretory dysfunction of the intrinsic factor, thus leading to malabsorption of vitamin B12 and hyperhomocysteinemia. In addition, chronic <italic toggle="yes">H. pylori</italic> infection has been shown to decrease secretion of ascorbic acid from the gastric mucosa and to increase gastric pH. Low ascorbic acid in gastric juice or high pH of gastric juice have been demonstrated to produce reduced dietary folate absorption, also leading to hyperhomocysteinemia [<xref rid="B97-medicina-59-00504" ref-type="bibr">97</xref>]. Of note, plasma homocysteine concentrations can range from 5 to 15 &#x003bc;mol/L in normal people [<xref rid="B98-medicina-59-00504" ref-type="bibr">98</xref>], and elevated homocysteine levels of 15 &#x003bc;mol/L or higher are considered as indicators of hyperhomocysteinemia [<xref rid="B99-medicina-59-00504" ref-type="bibr">99</xref>]. </p><p>Hyperhomocysteinemia, as an atherogenic mediator, appears to be a risk factor for cardio-cerebrovascular diseases and AD, the end-points of MetS [<xref rid="B62-medicina-59-00504" ref-type="bibr">62</xref>,<xref rid="B100-medicina-59-00504" ref-type="bibr">100</xref>] (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). Moreover, the three &#x0201c;non-conventional&#x0201d; coronary artery disease risk factors, including hyperhomocysteinemia, hyperfibrinogenemia, and high lipoprotein-a, may stimulate the existence of arteriosclerosis and sequelae such as neurodegeneration [<xref rid="B101-medicina-59-00504" ref-type="bibr">101</xref>,<xref rid="B102-medicina-59-00504" ref-type="bibr">102</xref>]. More specifically, hyperhomocysteinemia has been involved in the pathophysiology of neurodegenerative diseases including AD. As an indicator of AD, increased homocysteine levels raise A&#x003b2; concentrations and/or deposition, thereby contributing to cognitive deterioration [<xref rid="B79-medicina-59-00504" ref-type="bibr">79</xref>]. Increased homocysteine levels, with a subsequence insufficiency of methionine and S-Adenosyl-L-methionine and high S-Adenosyl-L-homocysteine, are linked with the reduced methylation capability. Inhibition of methylation reactions worsens the A&#x003b2; and tau pathologies also seen in <italic toggle="yes">H. pylori</italic>-associated AD [<xref rid="B79-medicina-59-00504" ref-type="bibr">79</xref>,<xref rid="B103-medicina-59-00504" ref-type="bibr">103</xref>]. Hyperfibrinogenemia also appears to be a risk factor of AD. An interaction between fibrinogen and A&#x003b2; in brain tissue with the possible creation of fibrinogen-A&#x003b2; plaques may be connected to cognitive dysfunction. High fibrinogen serum levels are associated with BCT [<xref rid="B104-medicina-59-00504" ref-type="bibr">104</xref>], and fibrinogen plus A&#x003b2; complex formation is a hallmark of AD. Moreover, lipoprotein-a has been documented as a crucial factor in creation of A&#x003b2; plaques and exacerbation of AD.</p><p>Cognitively normal older individuals with elevated plasma concentrations of A&#x003b2; exhibit lower cognitive performance and higher homocysteine concentrations and BCT compared with those with reduced A&#x003b2; concentrations. Especially, such individuals with elevated A&#x003b2;1-40 exhibit a thinner temporal lobe, poorer self-perception of daily memory, and hyperhomocysteinemia [<xref rid="B84-medicina-59-00504" ref-type="bibr">84</xref>]. Thinning of the temporal lobe appears to start eleven years before onset of cognitive impairment; BCT is a very sensitive indicator of neurodegenerative alterations, appearing decades before onset of AD clinical symptoms. Additional data also suggest that hyperhomocysteinemia is significantly associated with BCT, indicating cerebral atrophy in elderly asymptomatic populations [<xref rid="B105-medicina-59-00504" ref-type="bibr">105</xref>] (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). Our findings show that active <italic toggle="yes">H. pylori</italic> infection appears to contribute to the pathogenesis of mild cognitive impairment, a prodromic condition predisposing for subsequent development of AD, by triggering the following sequence: chronic atrophic gastritis - hyperhomocysteinemia - mild cognitive impairment - AD development [<xref rid="B23-medicina-59-00504" ref-type="bibr">23</xref>]. Since mild cognitive impairment is significantly connected with BCT [<xref rid="B106-medicina-59-00504" ref-type="bibr">106</xref>], further research is necessary to evaluate whether lowering plasma homocysteine concentrations in both asymptomatic people and mild cognitive impairment patients with <italic toggle="yes">H. pylori</italic> infection may prevent neurodegenerative changes or delay the progression to the development of dementia.</p><p>Specifically, hyperhomocysteinemia appears to play an active role in the pathophysiology of mild cognitive impairment &#x02013; AD sequence by triggering A&#x003b2; and tau pathologic conditions linked with synaptic dysfunction, neuroinflammatory process, and memory worsening (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). This finding signifies a potential novel strategy for the therapy of populations exhibiting this risk parameter [<xref rid="B107-medicina-59-00504" ref-type="bibr">107</xref>]. In this respect, apart from increased levels of homocysteine, other <italic toggle="yes">H. pylori</italic>-associated MetS conditions provoke the mentioned mild cognitive impairment &#x02013; AD sequence [<xref rid="B62-medicina-59-00504" ref-type="bibr">62</xref>]. Experimental evidence indicates that only live <italic toggle="yes">H. pylori</italic> filtrates injection and not <italic toggle="yes">Escherichia coli</italic> induce in rats spatial learning and memory insufficiency [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>]. Moreover, live <italic toggle="yes">H. pylori</italic> filtrates raise A&#x003b2;42 in the hippocampus and cortex by augmenting &#x003b3;-secretase activity, thus triggering cognitive deterioration via interruption of the synaptic function [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>] (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). Likewise, <italic toggle="yes">H. pylori</italic> filtrates stimulate tau hyperphosphorylation in rats at many AD-linked tau phosphorylation brain areas with activation of glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;) [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>] (<xref rid="medicina-59-00504-f002" ref-type="fig">Figure 2</xref>). </p><p>In contrast, GSK-3 inhibitors seem to attenuate the <italic toggle="yes">H. pylori</italic>-provoked tau hyperphosphorylation. These data provide an indication for potential involvement of <italic toggle="yes">H. pylori</italic> infection in AD comparable tau pathology and suggest that <italic toggle="yes">H. pylori</italic> eradication might exert a beneficial effect against tauopathy [<xref rid="B76-medicina-59-00504" ref-type="bibr">76</xref>]. The aforementioned experimental data seem to support our own clinical studies showing that <italic toggle="yes">H. pylori</italic> eradication may exert a positive effect on AD manifestations at 2- and 5-year survival endpoints [<xref rid="B108-medicina-59-00504" ref-type="bibr">108</xref>]. Persistent <italic toggle="yes">H. pylori</italic> infection above 3 years results in hyperhomocysteinemia in healthy people [<xref rid="B109-medicina-59-00504" ref-type="bibr">109</xref>]. Likewise, <italic toggle="yes">H. pylori</italic> eradication in a vitamin-B12-deficiency setting leads to increased vitamin B12 levels and reduced homocysteine blood levels [<xref rid="B110-medicina-59-00504" ref-type="bibr">110</xref>]. Therefore, additional studies are needed to clarify the influence of eradication of this bacterium in the following sequence: hyperhomocysteinemia-linked asymptomatic setting - mild cognitive impairment - AD.</p><p>PD, a major worldwide health problem also associated with AD [<xref rid="B111-medicina-59-00504" ref-type="bibr">111</xref>,<xref rid="B112-medicina-59-00504" ref-type="bibr">112</xref>], is a neurodegenerative disease of the CNS affecting primarily dopaminergic neurons in the substantia nigra.</p><p>Alpha-synuclein (&#x003b1;-synuclein) is a protein participating in the transport of synaptic vesicles and the release of neurotransmitters in the synaptic cleft. Moreover, the &#x003b1;-synuclein protein is crucially involved in PD pathology, as the aggregation of &#x003b1;-synuclein is associated with neuron loss in PD. More specifically, &#x003b1;-synuclein misfolding leads to toxicity mediated by a-synuclein aggregates, namely protofibrils, that cause loss of synapses and neuronal death (<xref rid="medicina-59-00504-f001" ref-type="fig">Figure 1</xref>). In this respect, &#x003b1;-synuclein-associated mutations, for instance, in the SNCA gene, are related not only with familial PD but also predispose to sporadic disease. Pathological mechanisms that also contribute in PD evolution are mitochondrial dysfunction, the production of reactive oxygen species and other oxidative species, defective calcium homeostasis, endoplasmic reticulum/Golgi impairment, and microglia activation in the context of neuroinflammation [<xref rid="B113-medicina-59-00504" ref-type="bibr">113</xref>]. Apart from the motor dysfunction in PD, non-motor symptoms have been the focus of extensive research, such as impairment of olfaction, mood disorders, and cognitive deficit [<xref rid="B114-medicina-59-00504" ref-type="bibr">114</xref>,<xref rid="B115-medicina-59-00504" ref-type="bibr">115</xref>]. Advanced neuroimaging biomarkers have been increasingly under study in the context of PD, and their association with cognitive function and other non-motor symptoms is under thorough investigation. More specifically, in PD, BCT has been associated with mild cognitive impairment [<xref rid="B116-medicina-59-00504" ref-type="bibr">116</xref>] and rapid eye movement sleep behavior disorder [<xref rid="B117-medicina-59-00504" ref-type="bibr">117</xref>], whereas it has been suggested as a possible biomarker with prognostic potential [<xref rid="B118-medicina-59-00504" ref-type="bibr">118</xref>,<xref rid="B119-medicina-59-00504" ref-type="bibr">119</xref>]. Changes in cortical thickness may lead to a dysfunction of resting-state functional connectivity, contributing to cognitive decline in patients with PD [<xref rid="B69-medicina-59-00504" ref-type="bibr">69</xref>].</p><p>Recent meta-analysis indicates that both PD and AD are significantly linked with gastrointestinal disorders including <italic toggle="yes">H. pylori</italic> infection. Therefore, the adverse role of <italic toggle="yes">H. pylori</italic> in the pathophysiology of PD or AD should be evaluated to shed new light on the diagnosis and therapy of PD and AD [<xref rid="B120-medicina-59-00504" ref-type="bibr">120</xref>]. </p><p>Focusing on <italic toggle="yes">H. pylori</italic>-related PD, relative data indicate that <italic toggle="yes">H. pylori</italic> infection may play a role in PD pathophysiology. There is a strong association between <italic toggle="yes">H. pylori</italic> chronic infection-related gastric pathologies and exacerbation of PD symptoms [<xref rid="B121-medicina-59-00504" ref-type="bibr">121</xref>]. A large cross-sectional study demonstrated a positive connection among <italic toggle="yes">H. pylori</italic> positivity (detected by <sup>13</sup>C-urea breath test) and PD motor severity [<xref rid="B121-medicina-59-00504" ref-type="bibr">121</xref>]. Likewise, <italic toggle="yes">H. pylori</italic> infection and MetS are important risk factors for PD [<xref rid="B66-medicina-59-00504" ref-type="bibr">66</xref>]. Apoptotic microglia-associated nerve cell death seems to underlie PD and other common neurological conditions including AD, multiple sclerosis, and glaucoma, which are also associated with <italic toggle="yes">H. pylori</italic> infection [<xref rid="B66-medicina-59-00504" ref-type="bibr">66</xref>].</p><p>In this regard, hyperhomocysteinemia could drive PD development and progression via many pathways involving apoptosis, oxidative stress, mitochondrial dysfunction, and DNA damage in nerve cells [<xref rid="B122-medicina-59-00504" ref-type="bibr">122</xref>]. In PD, hyperhomocysteinemia seems to be connected with cognitive performance and structural damage in the cerebral cortex [<xref rid="B123-medicina-59-00504" ref-type="bibr">123</xref>]. Hyperhomocysteinemia is a risk factor for cognitive decline in PD [<xref rid="B124-medicina-59-00504" ref-type="bibr">124</xref>]. Thus, hyperhomocysteinemia during PD development and progression offers a novel strategy for the diagnosis and treatment of PD [<xref rid="B122-medicina-59-00504" ref-type="bibr">122</xref>]. Relative data indicate the occurrence of hyperhomocysteinemia in levodopa-treated PD patients, whereas vitamin B12 and folate supplementation may decrease homocysteine levels [<xref rid="B125-medicina-59-00504" ref-type="bibr">125</xref>]. Likewise, <italic toggle="yes">H. pylori</italic> eradication in patients with PD might improve the bioavailability of L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopamine used as a treatment for PD, and reduce motor fluctuations [<xref rid="B111-medicina-59-00504" ref-type="bibr">111</xref>]. In addition, <italic toggle="yes">H. pylori,</italic> which selectively infects and colonizes predominantly the gastric epithelium and oral cavity [<xref rid="B126-medicina-59-00504" ref-type="bibr">126</xref>], is a risk factor for periodontitis [<xref rid="B127-medicina-59-00504" ref-type="bibr">127</xref>]; periodontitis, beyond AD [<xref rid="B53-medicina-59-00504" ref-type="bibr">53</xref>], is linked with PD [<xref rid="B128-medicina-59-00504" ref-type="bibr">128</xref>,<xref rid="B129-medicina-59-00504" ref-type="bibr">129</xref>]. In contrast, <italic toggle="yes">H. pylori</italic> eradication and treatment of periodontitis are beneficial for the prevention of PD and dementia [<xref rid="B127-medicina-59-00504" ref-type="bibr">127</xref>].</p><p>Equivalent data may also be obtained for clinically isolated syndrome - multiple sclerosis sequence [<xref rid="B25-medicina-59-00504" ref-type="bibr">25</xref>,<xref rid="B28-medicina-59-00504" ref-type="bibr">28</xref>,<xref rid="B130-medicina-59-00504" ref-type="bibr">130</xref>]. Indeed, our studies show that active <italic toggle="yes">H. pylori</italic> infection, apart from multiple sclerosis [<xref rid="B28-medicina-59-00504" ref-type="bibr">28</xref>,<xref rid="B130-medicina-59-00504" ref-type="bibr">130</xref>], is also common in clinically isolated syndrome, a prodromic condition predisposing for subsequent development of multiple sclerosis, accompanied by increased homocysteine levels. Moreover, eradication of this bacterium could constrain the progression of clinically isolated syndrome to the development of multiple sclerosis [<xref rid="B25-medicina-59-00504" ref-type="bibr">25</xref>]; BCT is observed in both clinically isolated syndrome and multiple sclerosis [<xref rid="B130-medicina-59-00504" ref-type="bibr">130</xref>]. In addition, recent data indicate that hyperhomocysteinemia, beyond cardiovascular disorders, appears to be an important factor involved in the pathogenesis of such an autoimmune disease of the CNS system as multiple sclerosis; it plays a role in endothelial dysfunction in multiple sclerosis [<xref rid="B131-medicina-59-00504" ref-type="bibr">131</xref>]. Hyperhomocysteinemia is linked with high process activity and disease progression by involving in the mechanisms of neurodegeneration observed in multiple sclerosis. Thus, homocysteine concentration may be a potential marker predicting the course of the disease [<xref rid="B132-medicina-59-00504" ref-type="bibr">132</xref>]. Another study reported higher homocysteine blood levels in patients with progressive multiple sclerosis compared to patients with relapsing-remitting multiple sclerosis [<xref rid="B133-medicina-59-00504" ref-type="bibr">133</xref>]. Of note, progressive multiple sclerosis is a form of the disease typically considered to exhibit higher neurodegenerative components in terms of underlying pathology, whereas relapsing-remitting multiple sclerosis is primarily characterized by increased relative contribution of neuroinflammation in the disease pathology [<xref rid="B134-medicina-59-00504" ref-type="bibr">134</xref>]. In this respect, the findings of the study underline a possible mechanism by which <italic toggle="yes">H. pylori</italic> infection and <italic toggle="yes">H. pylori</italic> infection-related hyperhomocysteinemia may contribute to neurodegeneration in the context of multiple sclerosis.</p><p>Glaucoma, the leading cause of irreversible blindness worldwide, is linked with both PD and AD [<xref rid="B135-medicina-59-00504" ref-type="bibr">135</xref>]. </p><p>Specifically, active <italic toggle="yes">H. pylori</italic> infection, beyond PD, is also associated with primary open-angle glaucoma, which has been called &#x0201c;ocular AD&#x0201d;, and pseudo-exfoliative glaucoma in some populations studied [<xref rid="B136-medicina-59-00504" ref-type="bibr">136</xref>,<xref rid="B137-medicina-59-00504" ref-type="bibr">137</xref>,<xref rid="B138-medicina-59-00504" ref-type="bibr">138</xref>]. Moreover, <italic toggle="yes">H. pylori</italic> eradication seems to improve glaucoma parameters, thereby signifying a potential causal relationship between <italic toggle="yes">H. pylori</italic> infection and glaucoma [<xref rid="B136-medicina-59-00504" ref-type="bibr">136</xref>]. Glaucoma induces the death of retinal ganglion cells and their axons and appears to be the second most common reason of blindness worldwide [<xref rid="B138-medicina-59-00504" ref-type="bibr">138</xref>]. Although glaucoma is frequently considered an eye-only disorder, relative data suggest the involvement of the brain&#x02019;s visual system in glaucoma. Post-mortem histology has disclosed that signs of neurodegeneration and associated metabolic changes are not restricted to retinal ganglion cells and the optic nerve but encompass upstream parts of the central visual pathway including the visual cortex. According to the mentioned BCT analyses, cortical degeneration within the visual areas becomes progressively aggravated with the augmenting severity of primary open-angle glaucoma [<xref rid="B139-medicina-59-00504" ref-type="bibr">139</xref>]. The cortical thinning of visual areas might play a key role in the progression of glaucoma and can be a novel biomarker for assessing the severity of glaucoma [<xref rid="B139-medicina-59-00504" ref-type="bibr">139</xref>]. Moreover, the inner retinal layer thinning, optic nerve cupping, and reduced visual cortex activity may occur before patients show visual field impairment [<xref rid="B72-medicina-59-00504" ref-type="bibr">72</xref>].</p><p>In this respect, hyperhomocysteinemia may play a role in the pathogenesis of retinal diseases, especially glaucoma and age-related macular degeneration [<xref rid="B140-medicina-59-00504" ref-type="bibr">140</xref>]. Oxidative stress and mitochondrial dysfunction are main mediators involved in the pathogenesis of neurodegenerative and in inner retinal neurodegenerative disorders. These mediators are also mediators of hyperhomocysteinemia-induced neuronal retinal ganglion cells death [<xref rid="B141-medicina-59-00504" ref-type="bibr">141</xref>]; and oxidative stress is a major pathogenic mechanism related to hyperhomocysteinemia. Particularly, as in the case of <italic toggle="yes">H. pylori</italic> infection [<xref rid="B137-medicina-59-00504" ref-type="bibr">137</xref>,<xref rid="B138-medicina-59-00504" ref-type="bibr">138</xref>,<xref rid="B142-medicina-59-00504" ref-type="bibr">142</xref>], hyperhomocysteinemia induces endothelial dysfunction and is associated with primary open-angle glaucoma and/or pseudo-exfoliation glaucoma, thereby signifying the potential prevention and therapy of glaucoma by regulating homocysteine levels [<xref rid="B143-medicina-59-00504" ref-type="bibr">143</xref>]. Moreover, nutritional disturbances seem to be connected with an augmented risk of glaucoma [<xref rid="B139-medicina-59-00504" ref-type="bibr">139</xref>], and the treatment of hyperhomocysteinemia by receiving low-cost vitamin B12 and folic acid regimens may prevent vascular abnormalities of this disorder [<xref rid="B144-medicina-59-00504" ref-type="bibr">144</xref>]. Of note, early and long-term vitamin B12 supplementation may offer benefits against cognitive decline [<xref rid="B145-medicina-59-00504" ref-type="bibr">145</xref>]. Nevertheless, whether <italic toggle="yes">H. pylori</italic> eradication, beyond other glaucoma parameters, offers an additional benefit regarding hyperhomocysteinemia-associated glaucoma remains to be elucidated in the future.</p><p>Finally, BCT in schizophrenia might be correlated with subsequent suicidal behavior [<xref rid="B146-medicina-59-00504" ref-type="bibr">146</xref>]. In this regard, hyperhomocysteinemia appears to play a role in the pathophysiology of schizophrenia; hyperhomocysteinemia is correlated with negative symptoms of schizophrenia [<xref rid="B147-medicina-59-00504" ref-type="bibr">147</xref>], and it may serve as a prognostic marker for schizophrenia [<xref rid="B148-medicina-59-00504" ref-type="bibr">148</xref>]. Likewise, <italic toggle="yes">H. pylori</italic> has been proposed to play a role as a potential environmental factor for pathogenesis of schizophrenia [<xref rid="B149-medicina-59-00504" ref-type="bibr">149</xref>], and <italic toggle="yes">H. pylori</italic> infection, associated with homocysteine changes, might contribute to schizophrenia development [<xref rid="B150-medicina-59-00504" ref-type="bibr">150</xref>]. Moreover, both schizophrenia and <italic toggle="yes">H. pylori</italic> infection have been correlated with malnutrition [<xref rid="B151-medicina-59-00504" ref-type="bibr">151</xref>,<xref rid="B152-medicina-59-00504" ref-type="bibr">152</xref>], and <italic toggle="yes">H. pylori</italic> infection, among others, induces the reduced bioavailability or the malabsorption of essential nutrients such as the mentioned vitamin B12 and folate, leading to hyperhomocysteinemia [<xref rid="B151-medicina-59-00504" ref-type="bibr">151</xref>]. Vitamin supplementation, especially with low-cost vitamin B12, folate, and vitamin D, could offer significant benefits in the treatment of schizophrenia [<xref rid="B153-medicina-59-00504" ref-type="bibr">153</xref>] and could improve the <italic toggle="yes">H. pylori</italic> eradication rate [<xref rid="B154-medicina-59-00504" ref-type="bibr">154</xref>]. Nevertheless, whether <italic toggle="yes">H. pylori</italic> eradication may also offer benefit in the treatment of schizophrenia requires further investigation.</p><p>In conclusion, controlling the impact of <italic toggle="yes">H. pylori</italic>-related hyperhomocysteinemia on such neurodegenerative disorders might offer benefits, and additional research is warranted to clarify this crucial topic currently representing a major global burden.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>J.K. conceptualized the idea, developed the original draft, and finalized the manuscript; M.D., A.P., S.A.P., C.Z., E.K., S.A., F.K., M.C.M., M.B. and E.V. critically reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable for opinion article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicina-59-00504"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yadav</surname><given-names>P.</given-names></name>
<name><surname>Lee</surname><given-names>Y.-H.</given-names></name>
<name><surname>Panday</surname><given-names>H.</given-names></name>
<name><surname>Kant</surname><given-names>S.</given-names></name>
<name><surname>Bajwa</surname><given-names>N.</given-names></name>
<name><surname>Parashar</surname><given-names>R.</given-names></name>
<name><surname>Jha</surname><given-names>S.K.</given-names></name>
<name><surname>Jha</surname><given-names>N.K.</given-names></name>
<name><surname>Nand</surname><given-names>P.</given-names></name>
<name><surname>Lee</surname><given-names>S.S.</given-names></name>
<etal/>
</person-group><article-title>Implications of Microorganisms in Alzheimer&#x02019;s Disease</article-title><source>Curr. Issues Mol. Biol.</source><year>2022</year><volume>44</volume><fpage>4584</fpage><lpage>4615</lpage><pub-id pub-id-type="doi">10.3390/cimb44100314</pub-id><pub-id pub-id-type="pmid">36286029</pub-id></element-citation></ref><ref id="B2-medicina-59-00504"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Kotronis</surname><given-names>G.</given-names></name>
<name><surname>Gialamprinou</surname><given-names>D.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Alzheimer&#x02019;s disease and gastrointestinal microbiota; impact of <italic toggle="yes">Helicobacter pylori</italic> infection involvement</article-title><source>Int. J. Neurosci.</source><year>2021</year><volume>131</volume><fpage>289</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1080/00207454.2020.1738432</pub-id><pub-id pub-id-type="pmid">32125206</pub-id></element-citation></ref><ref id="B3-medicina-59-00504"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sait</surname><given-names>A.</given-names></name>
<name><surname>Angeli</surname><given-names>C.</given-names></name>
<name><surname>Doig</surname><given-names>A.J.</given-names></name>
<name><surname>Day</surname><given-names>P.J.R.</given-names></name>
</person-group><article-title>Viral Involvement in Alzheimer&#x02019;s Disease</article-title><source>ACS Chem. Neurosci.</source><year>2021</year><volume>12</volume><fpage>1049</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00719</pub-id><pub-id pub-id-type="pmid">33687205</pub-id></element-citation></ref><ref id="B4-medicina-59-00504"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alegret</surname><given-names>M.</given-names></name>
<name><surname>Vinyes-Junqu&#x000e9;</surname><given-names>G.</given-names></name>
<name><surname>Boada</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez-Lage</surname><given-names>P.</given-names></name>
<name><surname>Cuberas</surname><given-names>G.</given-names></name>
<name><surname>Espinosa</surname><given-names>A.</given-names></name>
<name><surname>Roca</surname><given-names>I.</given-names></name>
<name><surname>Hern&#x000e0;ndez</surname><given-names>I.</given-names></name>
<name><surname>Valero</surname><given-names>S.</given-names></name>
<name><surname>Rosende-Roca</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Brain Perfusion Correlates of Visuoperceptual Deficits in Mild Cognitive Impairment and Mild Alzheimer&#x02019;s Disease</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2010</year><volume>21</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-091069</pub-id><pub-id pub-id-type="pmid">20555146</pub-id></element-citation></ref><ref id="B5-medicina-59-00504"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fjell</surname><given-names>A.M.</given-names></name>
<name><surname>Walhovd</surname><given-names>K.B.</given-names></name>
</person-group><article-title>Structural Brain Changes in Aging: Courses, Causes and Cognitive Consequences</article-title><source>Rev. Neurosci.</source><year>2010</year><volume>21</volume><fpage>187</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1515/REVNEURO.2010.21.3.187</pub-id><pub-id pub-id-type="pmid">20879692</pub-id></element-citation></ref><ref id="B6-medicina-59-00504"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>K.H.</given-names></name>
<name><surname>Choi</surname><given-names>K.Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.J.</given-names></name>
<name><surname>Kim</surname><given-names>B.C.</given-names></name>
<name><surname>Kwon</surname><given-names>G.-R.</given-names></name>
</person-group><article-title>Alzheimer&#x02019;s Disease Diagnosis Based on Cortical and Subcortical Features</article-title><source>J. Healthc. Eng.</source><year>2019</year><volume>2019</volume><fpage>2492719</fpage><pub-id pub-id-type="doi">10.1155/2019/2492719</pub-id><pub-id pub-id-type="pmid">30944718</pub-id></element-citation></ref><ref id="B7-medicina-59-00504"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zarei</surname><given-names>M.</given-names></name>
<name><surname>Ibarretxe-Bilbao</surname><given-names>N.</given-names></name>
<name><surname>Compta</surname><given-names>Y.</given-names></name>
<name><surname>Hough</surname><given-names>M.</given-names></name>
<name><surname>Junque</surname><given-names>C.</given-names></name>
<name><surname>Bargallo</surname><given-names>N.</given-names></name>
<name><surname>Tolosa</surname><given-names>E.</given-names></name>
<name><surname>Jose Mart&#x000ed;</surname><given-names>M.</given-names></name>
</person-group><article-title>Cortical thinning is associated with disease stages and dementia in Parkinson&#x02019;s disease</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2013</year><volume>84</volume><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-304126</pub-id><pub-id pub-id-type="pmid">23463873</pub-id></element-citation></ref><ref id="B8-medicina-59-00504"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Hattori</surname><given-names>T.</given-names></name>
<name><surname>Tomisato</surname><given-names>H.</given-names></name>
<name><surname>Ohara</surname><given-names>M.</given-names></name>
<name><surname>Hirata</surname><given-names>K.</given-names></name>
<name><surname>Yokota</surname><given-names>T.</given-names></name>
</person-group><article-title>Turning and multitask gait unmask gait disturbance in mild-to-moderate multiple sclerosis: Underlying specific cortical thinning and connecting fibers damage</article-title><source>Hum. Brain Mapp.</source><year>2023</year><volume>44</volume><fpage>1193</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1002/hbm.26151</pub-id><pub-id pub-id-type="pmid">36409700</pub-id></element-citation></ref><ref id="B9-medicina-59-00504"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Shah</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Sweeney</surname><given-names>J.A.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Gong</surname><given-names>Q.</given-names></name>
</person-group><article-title>Cortical Thickness Abnormalities at Different Stages of the Illness Course in Schizophrenia</article-title><source>JAMA Psychiatry</source><year>2022</year><volume>79</volume><fpage>560</fpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.0799</pub-id><pub-id pub-id-type="pmid">35476125</pub-id></element-citation></ref><ref id="B10-medicina-59-00504"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>C.P.-W.</given-names></name>
<name><surname>Cheng</surname><given-names>S.-T.</given-names></name>
<name><surname>Tam</surname><given-names>C.W.-C.</given-names></name>
<name><surname>Chan</surname><given-names>W.-C.</given-names></name>
<name><surname>Chu</surname><given-names>W.C.-W.</given-names></name>
<name><surname>Lam</surname><given-names>L.C.-W.</given-names></name>
</person-group><article-title>Relationship between Cortical Thickness and Neuropsychological Performance in Normal Older Adults and Those with Mild Cognitive Impairment</article-title><source>Aging Dis.</source><year>2018</year><volume>9</volume><fpage>1020</fpage><pub-id pub-id-type="doi">10.14336/AD.2018.0125</pub-id><pub-id pub-id-type="pmid">30574415</pub-id></element-citation></ref><ref id="B11-medicina-59-00504"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Machulda</surname><given-names>M.M.</given-names></name>
<name><surname>Lundt</surname><given-names>E.S.</given-names></name>
<name><surname>Albertson</surname><given-names>S.M.</given-names></name>
<name><surname>Spychalla</surname><given-names>A.J.</given-names></name>
<name><surname>Schwarz</surname><given-names>C.G.</given-names></name>
<name><surname>Mielke</surname><given-names>M.M.</given-names></name>
<name><surname>Jack</surname><given-names>C.R.</given-names></name>
<name><surname>Kremers</surname><given-names>W.K.</given-names></name>
<name><surname>Vemuri</surname><given-names>P.</given-names></name>
<name><surname>Knopman</surname><given-names>D.S.</given-names></name>
<etal/>
</person-group><article-title>Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging</article-title><source>Alzheimer&#x02019;s Dement.</source><year>2020</year><volume>16</volume><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1002/alz.12108</pub-id><pub-id pub-id-type="pmid">32418367</pub-id></element-citation></ref><ref id="B12-medicina-59-00504"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>J.P.</given-names></name>
<name><surname>Pierce</surname><given-names>M.E.</given-names></name>
<name><surname>Brown</surname><given-names>E.</given-names></name>
<name><surname>Salat</surname><given-names>D.</given-names></name>
<name><surname>Logue</surname><given-names>M.W.</given-names></name>
<name><surname>Constantinescu</surname><given-names>J.</given-names></name>
<name><surname>Valerio</surname><given-names>K.</given-names></name>
<name><surname>Miller</surname><given-names>M.W.</given-names></name>
<name><surname>Sherva</surname><given-names>R.</given-names></name>
<name><surname>Huber</surname><given-names>B.R.</given-names></name>
<etal/>
</person-group><article-title>Genetic Risk for Alzheimer Disease and Plasma Tau Are Associated With Accelerated Parietal Cortex Thickness Change in Middle-Aged Adults</article-title><source>Neurol. Genet.</source><year>2023</year><volume>9</volume><fpage>e200053</fpage><pub-id pub-id-type="doi">10.1212/NXG.0000000000200053</pub-id><pub-id pub-id-type="pmid">36742995</pub-id></element-citation></ref><ref id="B13-medicina-59-00504"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sampedro</surname><given-names>F.</given-names></name>
<name><surname>Puig-Davi</surname><given-names>A.</given-names></name>
<name><surname>Martinez-Horta</surname><given-names>S.</given-names></name>
<name><surname>Pagonabarraga</surname><given-names>J.</given-names></name>
<name><surname>Horta-Barba</surname><given-names>A.</given-names></name>
<name><surname>Aracil-Bola&#x000f1;os</surname><given-names>I.</given-names></name>
<name><surname>Kulisevsky</surname><given-names>J.</given-names></name>
</person-group><article-title>Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson&#x02019;s disease</article-title><source>Clin. Neurol. Neurosurg.</source><year>2023</year><volume>224</volume><fpage>107531</fpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2022.107531</pub-id></element-citation></ref><ref id="B14-medicina-59-00504"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Masurkar</surname><given-names>A.V.</given-names></name>
<name><surname>Khasiyev</surname><given-names>F.</given-names></name>
<name><surname>Rundek</surname><given-names>T.</given-names></name>
<name><surname>Wright</surname><given-names>C.B.</given-names></name>
<name><surname>Elkind</surname><given-names>M.S.V.</given-names></name>
<name><surname>Sacco</surname><given-names>R.L.</given-names></name>
<name><surname>Gutierrez</surname><given-names>J.</given-names></name>
</person-group><article-title>Intracranial artery stenosis is associated with cortical thinning in stroke-free individuals of two longitudinal cohorts</article-title><source>J. Neurol. Sci.</source><year>2023</year><volume>444</volume><fpage>120533</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2022.120533</pub-id><pub-id pub-id-type="pmid">36577280</pub-id></element-citation></ref><ref id="B15-medicina-59-00504"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dounavi</surname><given-names>M.-E.</given-names></name>
<name><surname>Newton</surname><given-names>C.</given-names></name>
<name><surname>Jenkins</surname><given-names>N.</given-names></name>
<name><surname>Mak</surname><given-names>E.</given-names></name>
<name><surname>Low</surname><given-names>A.</given-names></name>
<name><surname>Muniz-Terrera</surname><given-names>G.</given-names></name>
<name><surname>Williams</surname><given-names>G.B.</given-names></name>
<name><surname>Lawlor</surname><given-names>B.</given-names></name>
<name><surname>Naci</surname><given-names>L.</given-names></name>
<name><surname>Malhotra</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Macrostructural brain alterations at midlife are connected to cardiovascular and not inherited risk of future dementia: The PREVENT-Dementia study</article-title><source>J. Neurol.</source><year>2022</year><volume>269</volume><fpage>4299</fpage><lpage>4309</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11061-7</pub-id><pub-id pub-id-type="pmid">35279756</pub-id></element-citation></ref><ref id="B16-medicina-59-00504"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaw</surname><given-names>M.E.</given-names></name>
<name><surname>Abhayaratna</surname><given-names>W.P.</given-names></name>
<name><surname>Sachdev</surname><given-names>P.S.</given-names></name>
<name><surname>Anstey</surname><given-names>K.J.</given-names></name>
<name><surname>Cherbuin</surname><given-names>N.</given-names></name>
</person-group><article-title>Cortical Thinning at Midlife: The PATH Through Life Study</article-title><source>Brain Topogr.</source><year>2016</year><volume>29</volume><fpage>875</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1007/s10548-016-0509-z</pub-id><pub-id pub-id-type="pmid">27449323</pub-id></element-citation></ref><ref id="B17-medicina-59-00504"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vidal-Pi&#x000f1;eiro</surname><given-names>D.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>&#x000d8;.</given-names></name>
<name><surname>Blennow</surname><given-names>K.</given-names></name>
<name><surname>Capogna</surname><given-names>E.</given-names></name>
<name><surname>Halaas</surname><given-names>N.B.</given-names></name>
<name><surname>Idland</surname><given-names>A.-V.</given-names></name>
<name><surname>Mowinclkel</surname><given-names>A.M.</given-names></name>
<name><surname>Pereira</surname><given-names>J.B.</given-names></name>
<name><surname>Watne</surname><given-names>L.O.</given-names></name>
<name><surname>Zwttweberg</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults</article-title><source>Neurobiol. Aging</source><year>2022</year><volume>116</volume><fpage>80</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2022.04.010</pub-id><pub-id pub-id-type="pmid">35584575</pub-id></element-citation></ref><ref id="B18-medicina-59-00504"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itzhaki</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Herpes and Alzheimer&#x02019;s Disease: Subversion in the Central Nervous System and How It Might Be Halted</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2016</year><volume>54</volume><fpage>1273</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.3233/JAD-160607</pub-id><pub-id pub-id-type="pmid">27497484</pub-id></element-citation></ref><ref id="B19-medicina-59-00504"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fr&#x000f6;lich</surname><given-names>L.</given-names></name>
</person-group><article-title>Alzheimer&#x02019;s disease&#x02014;The &#x02018;microbial hypothesis&#x02019; from a clinical and neuroimaging perspective</article-title><source>Psychiatry Res. Neuroimaging</source><year>2020</year><volume>306</volume><fpage>111181</fpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2020.111181</pub-id><pub-id pub-id-type="pmid">32919870</pub-id></element-citation></ref><ref id="B20-medicina-59-00504"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>N.</given-names></name>
<name><surname>Tsolaki</surname><given-names>M.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Tzilves</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Increased Cerebrospinal Fluid <italic toggle="yes">Helicobacter pylori</italic> Antibody in Alzheimer&#x02019;s Disease</article-title><source>Int. J. Neurosci.</source><year>2009</year><volume>119</volume><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1080/00207450902782083</pub-id><pub-id pub-id-type="pmid">19326283</pub-id></element-citation></ref><ref id="B21-medicina-59-00504"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Tsolaki</surname><given-names>M.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Karatzoglou</surname><given-names>P.</given-names></name>
<name><surname>Chatopoulow</surname><given-names>D.</given-names></name>
<name><surname>Venizelos</surname><given-names>I.</given-names></name>
</person-group><article-title>Relationship between <italic toggle="yes">Helicobacter pylori</italic> infection and Alzheimer disease</article-title><source>Neurology</source><year>2006</year><volume>66</volume><fpage>938</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000203644.68059.5f</pub-id><pub-id pub-id-type="pmid">16567719</pub-id></element-citation></ref><ref id="B22-medicina-59-00504"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Liatsos</surname><given-names>C.</given-names></name>
<name><surname>Tzitiridou-Chatzopoulou</surname><given-names>M.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Gilambrinou</surname><given-names>D.</given-names></name>
<name><surname>Kotronis</surname><given-names>G.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
</person-group><article-title>Potential impact of <italic toggle="yes">Helicobacter pylori</italic> and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease</article-title><source>Metabolism</source><year>2022</year><volume>135</volume><fpage>155276</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2022.155276</pub-id><pub-id pub-id-type="pmid">35940250</pub-id></element-citation></ref><ref id="B23-medicina-59-00504"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Tsolaki</surname><given-names>M.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Stergiopoulos</surname><given-names>C.</given-names></name>
<name><surname>Kapetanakis</surname><given-names>N.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
<name><surname>Venizelos</surname><given-names>I.</given-names></name>
</person-group><article-title>Association between <italic toggle="yes">Helicobacter pylori</italic> infection and mild cognitive impairment</article-title><source>Eur. J. Neurol.</source><year>2007</year><volume>14</volume><fpage>976</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2007.01827.x</pub-id><pub-id pub-id-type="pmid">17718688</pub-id></element-citation></ref><ref id="B24-medicina-59-00504"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
</person-group><article-title>Potential impact of <italic toggle="yes">Helicobacter pylori</italic>-related human &#x003b2;-defensin-1 on hepatic encephalopathy and neurodegeneration</article-title><source>Ann. Gastroenterol.</source><year>2016</year><volume>29</volume><fpage>99</fpage></element-citation></ref><ref id="B25-medicina-59-00504"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Tsiptsios</surname><given-names>D.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Venizelos</surname><given-names>I.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Koutlas</surname><given-names>E.</given-names></name>
<name><surname>Tsiptsios</surname><given-names>I.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Impact of <italic toggle="yes">Helicobacter pylori</italic> on multiple sclerosis-related clinically isolated syndrome</article-title><source>Acta Neurol. Scand.</source><year>2016</year><volume>133</volume><fpage>268</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/ane.12453</pub-id><pub-id pub-id-type="pmid">26079721</pub-id></element-citation></ref><ref id="B26-medicina-59-00504"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zeglinas</surname><given-names>C.</given-names></name>
<name><surname>Tzivras</surname><given-names>D.</given-names></name>
<name><surname>Romiopoulos</surname><given-names>I.</given-names></name>
<name><surname>Giorgakis</surname><given-names>N.</given-names></name>
<name><surname>Anastasiadou</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Impact of reactive oxygen species generation on <italic toggle="yes">Helicobacter pylori</italic>-related extragastric diseases: A hypothesis</article-title><source>Free Radic. Res.</source><year>2017</year><volume>51</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1080/10715762.2016.1271122</pub-id><pub-id pub-id-type="pmid">28095729</pub-id></element-citation></ref><ref id="B27-medicina-59-00504"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Kazakos</surname><given-names>E.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Kotronis</surname><given-names>G.</given-names></name>
<name><surname>Giartza-Taxidou</surname><given-names>E.</given-names></name>
<name><surname>Laskaridis</surname><given-names>L.</given-names></name>
<name><surname>Tzivras</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>A potential impact of <italic toggle="yes">Helicobacter pylori</italic> -related galectin-3 in neurodegeneration</article-title><source>Neurochem. Int.</source><year>2018</year><volume>113</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.12.003</pub-id><pub-id pub-id-type="pmid">29246761</pub-id></element-citation></ref><ref id="B28-medicina-59-00504"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arjmandi</surname><given-names>D.</given-names></name>
<name><surname>Abdollahi</surname><given-names>A.</given-names></name>
<name><surname>Ardekani</surname><given-names>A.</given-names></name>
<name><surname>Razavian</surname><given-names>I.</given-names></name>
<name><surname>Razavian</surname><given-names>E.</given-names></name>
<name><surname>Sartip</surname><given-names>B.</given-names></name>
<name><surname>Mahjour</surname><given-names>S.</given-names></name>
<name><surname>Parsa</surname><given-names>H.</given-names></name>
<name><surname>Kyvanasi</surname><given-names>N.A.</given-names></name>
<name><surname>Marhoommirzabak</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> infection and risk of multiple sclerosis: An updated meta-analysis</article-title><source>Helicobacter</source><year>2022</year><volume>27</volume><fpage>e12927</fpage><pub-id pub-id-type="doi">10.1111/hel.12927</pub-id><pub-id pub-id-type="pmid">36046943</pub-id></element-citation></ref><ref id="B29-medicina-59-00504"><label>29.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<name><surname>Sankararaman</surname><given-names>S.</given-names></name>
<name><surname>Moosavi</surname><given-names>L.</given-names></name>
</person-group><article-title>Urea Breath Test. Book. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 January, 8 August 2022</article-title><comment>Available online: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK542286/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK542286/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-23">(accessed on 23 December 2022)</date-in-citation></element-citation></ref><ref id="B30-medicina-59-00504"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Tzivras</surname><given-names>D.</given-names></name>
<name><surname>Dardiotis</surname><given-names>E.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Giartza-Taxidou</surname><given-names>E.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A perspective on risk factors for esophageal adenocarcinoma: Emphasis on <italic toggle="yes">Helicobacter pylori</italic> infection</article-title><source>Ann. N. Y. Acad. Sci. USA</source><year>2019</year><volume>1452</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1111/nyas.14168</pub-id></element-citation></ref><ref id="B31-medicina-59-00504"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Influence of <italic toggle="yes">Helicobacter pylori</italic> -connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk</article-title><source>Liver Int.</source><year>2020</year><volume>40</volume><fpage>475</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1111/liv.14264</pub-id><pub-id pub-id-type="pmid">31566879</pub-id></element-citation></ref><ref id="B32-medicina-59-00504"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Zeglinas</surname><given-names>C.</given-names></name>
<name><surname>Artemaki</surname><given-names>F.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Giartza-Taxidou</surname><given-names>E.</given-names></name>
<name><surname>Tsivras</surname><given-names>D.</given-names></name>
<name><surname>Vlachaki</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Potential impact of <italic toggle="yes">Helicobacter pylori</italic>-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis</article-title><source>Metabolism</source><year>2018</year><volume>87</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2018.06.008</pub-id><pub-id pub-id-type="pmid">29936174</pub-id></element-citation></ref><ref id="B33-medicina-59-00504"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fagan-Garcia</surname><given-names>K.</given-names></name>
<name><surname>Geary</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>H.-J.</given-names></name>
<name><surname>McAlpine</surname><given-names>L.</given-names></name>
<name><surname>Walker</surname><given-names>E.</given-names></name>
<name><surname>Colquhoun</surname><given-names>A.</given-names></name>
<name><surname>van Zanten</surname><given-names>S.V.</given-names></name>
<name><surname>Girgis</surname><given-names>S.</given-names></name>
<name><surname>Archie</surname><given-names>B.</given-names></name>
<name><surname>Hanley</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Burden of disease from <italic toggle="yes">Helicobacter pylori</italic> infection in western Canadian Arctic communities</article-title><source>BMC Public Health</source><year>2019</year><volume>19</volume><elocation-id>730</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-019-7065-x</pub-id><pub-id pub-id-type="pmid">31185961</pub-id></element-citation></ref><ref id="B34-medicina-59-00504"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Soteriades</surname><given-names>E.S.</given-names></name>
<name><surname>Tzitiridou-Chatzopoulou</surname><given-names>M.</given-names></name>
<name><surname>Gkolfakis</surname><given-names>P.</given-names></name>
<name><surname>Karafyllidou</surname><given-names>K.</given-names></name>
<name><surname>Doulbris</surname><given-names>M.</given-names></name>
</person-group><article-title>Impact of <italic toggle="yes">Helicobacter pylori</italic>-Related Metabolic Syndrome Parameters on Arterial Hypertension</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>2351</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9112351</pub-id><pub-id pub-id-type="pmid">34835476</pub-id></element-citation></ref><ref id="B35-medicina-59-00504"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerges</surname><given-names>S.E.</given-names></name>
<name><surname>Alosh</surname><given-names>T.K.</given-names></name>
<name><surname>Khalil</surname><given-names>S.H.</given-names></name>
<name><surname>el Din</surname><given-names>M.M.W.</given-names></name>
</person-group><article-title>Relevance of <italic toggle="yes">Helicobacter pylori</italic> infection in Egyptian multiple sclerosis patients</article-title><source>Egypt J. Neurol. Psychiatr. Neurosurg.</source><year>2018</year><volume>54</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s41983-018-0043-x</pub-id><pub-id pub-id-type="pmid">30595647</pub-id></element-citation></ref><ref id="B36-medicina-59-00504"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooi</surname><given-names>J.K.Y.</given-names></name>
<name><surname>Lai</surname><given-names>W.Y.</given-names></name>
<name><surname>Ng</surname><given-names>W.K.</given-names></name>
<name><surname>Suen</surname><given-names>M.M.Y.</given-names></name>
<name><surname>Underwood</surname><given-names>F.E.</given-names></name>
<name><surname>Tanyingoh</surname><given-names>D.</given-names></name>
<name><surname>Malfertheiner</surname><given-names>P.</given-names></name>
<name><surname>Graham</surname><given-names>D.Y.</given-names></name>
<name><surname>Wong</surname><given-names>V.W.</given-names></name>
<name><surname>Wu</surname><given-names>J.C.Y.</given-names></name>
<etal/>
</person-group><article-title>Global Prevalence of <italic toggle="yes">Helicobacter pylori</italic> Infection: Systematic Review and Meta-Analysis</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.04.022</pub-id><pub-id pub-id-type="pmid">28456631</pub-id></element-citation></ref><ref id="B37-medicina-59-00504"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sijmons</surname><given-names>D.</given-names></name>
<name><surname>Guy</surname><given-names>A.J.</given-names></name>
<name><surname>Walduck</surname><given-names>A.K.</given-names></name>
<name><surname>Ramsland</surname><given-names>P.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> and the Role of Lipopolysaccharide Variation in Innate Immune Evasion</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>868225</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.868225</pub-id><pub-id pub-id-type="pmid">35634347</pub-id></element-citation></ref><ref id="B38-medicina-59-00504"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olnes</surname><given-names>M.J.</given-names></name>
<name><surname>Martinson</surname><given-names>H.A.</given-names></name>
</person-group><article-title>Recent advances in immune therapies for gastric cancer</article-title><source>Cancer Gene Ther.</source><year>2021</year><volume>28</volume><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1038/s41417-021-00310-y</pub-id><pub-id pub-id-type="pmid">33664460</pub-id></element-citation></ref><ref id="B39-medicina-59-00504"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lina</surname><given-names>T.T.</given-names></name>
</person-group><article-title>Immune evasion strategies used by <italic toggle="yes">Helicobacter pylori</italic></article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>12753</fpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i36.12753</pub-id><pub-id pub-id-type="pmid">25278676</pub-id></element-citation></ref><ref id="B40-medicina-59-00504"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miklossy</surname><given-names>J.</given-names></name>
<name><surname>McGeer</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Common mechanisms involved in Alzheimer&#x02019;s disease and type 2 diabetes: A key role of chronic bacterial infection and inflammation</article-title><source>Aging</source><year>2016</year><volume>8</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.18632/aging.100921</pub-id><pub-id pub-id-type="pmid">26961231</pub-id></element-citation></ref><ref id="B41-medicina-59-00504"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Concentrating on the Long Topic of Empirical or Not Conventional <italic toggle="yes">Helicobacter pylori</italic> Eradication Regimens</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2022</year><fpage>S1542-3565(22)01016-3</fpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.10.027</pub-id></element-citation></ref><ref id="B42-medicina-59-00504"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kazakos</surname><given-names>E.I.</given-names></name>
<name><surname>Dorrell</surname><given-names>N.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Comment on &#x0201c;Effect of biofilm formation by clinical isolates of <italic toggle="yes">Helicobacter pylori</italic> on the efflux-mediated resistance to commonly used antibiotics&#x0201d;</article-title><source>World J. Gastroenterol.</source><year>2017</year><volume>23</volume><fpage>6194</fpage><lpage>6196</lpage><pub-id pub-id-type="doi">10.3748/wjg.v23.i33.6194</pub-id><pub-id pub-id-type="pmid">28970736</pub-id></element-citation></ref><ref id="B43-medicina-59-00504"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Kazakos</surname><given-names>E.</given-names></name>
</person-group><article-title>A proposed role of human defensins in <italic toggle="yes">Helicobacter pylori</italic>-related neurodegenerative disorders</article-title><source>Med. Hypotheses</source><year>2014</year><volume>82</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2013.12.025</pub-id><pub-id pub-id-type="pmid">24472867</pub-id></element-citation></ref><ref id="B44-medicina-59-00504"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Memariani</surname><given-names>H.</given-names></name>
<name><surname>Memariani</surname><given-names>M.</given-names></name>
</person-group><article-title>Antibiofilm properties of cathelicidin LL-37: An in-depth review</article-title><source>World J. Microbiol. Biotechnol.</source><year>2023</year><volume>39</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.1007/s11274-023-03545-z</pub-id><pub-id pub-id-type="pmid">36781570</pub-id></element-citation></ref><ref id="B45-medicina-59-00504"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Kotronis</surname><given-names>G.</given-names></name>
<name><surname>Thomann</surname><given-names>R.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Gialamprinou</surname><given-names>D.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Impact of <italic toggle="yes">Helicobacter pylori</italic> on Alzheimer&#x02019;s disease: What do we know so far?</article-title><source>Helicobacter</source><year>2018</year><volume>23</volume><fpage>e12454</fpage><pub-id pub-id-type="doi">10.1111/hel.12454</pub-id></element-citation></ref><ref id="B46-medicina-59-00504"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sjomina</surname><given-names>O.</given-names></name>
<name><surname>Pavlova</surname><given-names>J.</given-names></name>
<name><surname>Niv</surname><given-names>Y.</given-names></name>
<name><surname>Leja</surname><given-names>M.</given-names></name>
</person-group><article-title>Epidemiology of <italic toggle="yes">Helicobacter pylori</italic> infection</article-title><source>Helicobacter</source><year>2018</year><volume>23</volume><fpage>e12514</fpage><pub-id pub-id-type="doi">10.1111/hel.12514</pub-id><pub-id pub-id-type="pmid">30203587</pub-id></element-citation></ref><ref id="B47-medicina-59-00504"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>G.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> Recurrence after Eradication Therapy in Jiangjin District, Chongqing, China</article-title><source>Gastroenterol. Res. Pract.</source><year>2020</year><volume>2020</volume><fpage>7510872</fpage><pub-id pub-id-type="doi">10.1155/2020/7510872</pub-id><pub-id pub-id-type="pmid">32328098</pub-id></element-citation></ref><ref id="B48-medicina-59-00504"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khor</surname><given-names>C.J.</given-names></name>
<name><surname>Fock</surname><given-names>K.M.</given-names></name>
<name><surname>Ng</surname><given-names>T.M.</given-names></name>
<name><surname>Teo</surname><given-names>E.K.</given-names></name>
<name><surname>Sim</surname><given-names>C.S.</given-names></name>
<name><surname>Tan</surname><given-names>A.L.</given-names></name>
<name><surname>Ng</surname><given-names>A.</given-names></name>
</person-group><article-title>Recurrence of <italic toggle="yes">Helicobacter pylori</italic> infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population</article-title><source>Singap. Med. J.</source><year>2000</year><volume>41</volume><fpage>382</fpage><lpage>386</lpage></element-citation></ref><ref id="B49-medicina-59-00504"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>L.Y.</given-names></name>
<name><surname>Lu</surname><given-names>H.P.</given-names></name>
<name><surname>Liu</surname><given-names>J.Z.</given-names></name>
</person-group><article-title>Recurrence of <italic toggle="yes">Helicobacter pylori</italic> infection</article-title><source>Chin. Med. J.</source><year>2019</year><volume>132</volume><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000000146</pub-id><pub-id pub-id-type="pmid">30897591</pub-id></element-citation></ref><ref id="B50-medicina-59-00504"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Wan</surname><given-names>J.H.</given-names></name>
<name><surname>Li</surname><given-names>X.Y.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Graham</surname><given-names>D.Y.</given-names></name>
<name><surname>Lu</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Systematic review with meta-analysis: The global recurrence rate of <italic toggle="yes">Helicobacter pylori</italic></article-title><source>Aliment. Pharmacol. Ther.</source><year>2017</year><volume>46</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1111/apt.14319</pub-id><pub-id pub-id-type="pmid">28892184</pub-id></element-citation></ref><ref id="B51-medicina-59-00504"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kini</surname><given-names>V.</given-names></name>
<name><surname>Mohanty</surname><given-names>I.</given-names></name>
<name><surname>Telang</surname><given-names>G.</given-names></name>
<name><surname>Vyas</surname><given-names>N.</given-names></name>
</person-group><article-title>Immunopathogenesis and distinct role of Th17 in periodontitis: A review</article-title><source>J. Oral Biosci.</source><year>2022</year><volume>64</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.job.2022.04.005</pub-id><pub-id pub-id-type="pmid">35489583</pub-id></element-citation></ref><ref id="B52-medicina-59-00504"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Huo</surname><given-names>L.</given-names></name>
<name><surname>DU</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Long-term follow-up of <italic toggle="yes">Helicobacter pylori</italic> reinfection and its risk factors after initial eradication: A large-scale multicentre, prospective open cohort, observational study</article-title><source>Emerg. Microbes Infect.</source><year>2020</year><volume>9</volume><fpage>548</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1737579</pub-id><pub-id pub-id-type="pmid">32160805</pub-id></element-citation></ref><ref id="B53-medicina-59-00504"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alvarenga</surname><given-names>M.O.P.</given-names></name>
<name><surname>Fraz&#x000e3;o</surname><given-names>D.R.</given-names></name>
<name><surname>de Matos</surname><given-names>I.G.</given-names></name>
<name><surname>Bittencourt</surname><given-names>L.O.</given-names></name>
<name><surname>Fagundes</surname><given-names>N.C.F.</given-names></name>
<name><surname>R&#x000f6;sing</surname><given-names>C.K.</given-names></name>
<name><surname>Maia</surname><given-names>L.C.</given-names></name>
<name><surname>Lima</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Is There Any Association Between Neurodegenerative Diseases and Periodontitis? A Systematic Review</article-title><source>Front. Aging Neurosci.</source><year>2021</year><volume>24</volume><pub-id pub-id-type="doi">10.3389/fnagi.2021.651437</pub-id></element-citation></ref><ref id="B54-medicina-59-00504"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Kiprowska</surname><given-names>M.</given-names></name>
<name><surname>Kansara</surname><given-names>T.</given-names></name>
<name><surname>Kansara</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
</person-group><article-title>Neuroinflammation: A Distal Consequence of Periodontitis</article-title><source>J. Dent. Res.</source><year>2022</year><volume>101</volume><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1177/00220345221102084</pub-id><pub-id pub-id-type="pmid">35708472</pub-id></element-citation></ref><ref id="B55-medicina-59-00504"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siriviriyakul</surname><given-names>P.</given-names></name>
<name><surname>Werawatganon</surname><given-names>D.</given-names></name>
<name><surname>Phetnoo</surname><given-names>N.</given-names></name>
<name><surname>Somanawat</surname><given-names>K.</given-names></name>
<name><surname>Chatsuwan</surname><given-names>T.</given-names></name>
<name><surname>Klaikeaw</surname><given-names>N.</given-names></name>
</person-group><article-title>Chay Genistein attenuated gastric inflammation and apoptosis in <italic toggle="yes">Helicobacter pylori</italic>-induced gastropathy in rats</article-title><source>BMC Gastroenterol.</source><year>2020</year><volume>20</volume><elocation-id>410</elocation-id><pub-id pub-id-type="doi">10.1186/s12876-020-01555-x</pub-id><pub-id pub-id-type="pmid">33297977</pub-id></element-citation></ref><ref id="B56-medicina-59-00504"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piscione</surname><given-names>M.</given-names></name>
<name><surname>Mazzone</surname><given-names>M.</given-names></name>
<name><surname>di Marcantonio</surname><given-names>M.C.</given-names></name>
<name><surname>Muraro</surname><given-names>R.</given-names></name>
<name><surname>Mincione</surname><given-names>G.</given-names></name>
</person-group><article-title>Eradication of <italic toggle="yes">Helicobacter pylori</italic> and Gastric Cancer: A Controversial Relationship</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>630852</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.630852</pub-id><pub-id pub-id-type="pmid">33613500</pub-id></element-citation></ref><ref id="B57-medicina-59-00504"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varesi</surname><given-names>A.</given-names></name>
<name><surname>Campagnoli</surname><given-names>L.I.M.</given-names></name>
<name><surname>Carrara</surname><given-names>A.</given-names></name>
<name><surname>Pola</surname><given-names>I.</given-names></name>
<name><surname>Floris</surname><given-names>E.</given-names></name>
<name><surname>Ricevuti</surname><given-names>G.</given-names></name>
<name><surname>Chirumbolo</surname><given-names>S.</given-names></name>
<name><surname>Pascale</surname><given-names>A.</given-names></name>
</person-group><article-title>Non-Enzymatic Antioxidants against Alzheimer&#x02019;s Disease: Prevention, Diagnosis and Therapy</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12010180</pub-id><pub-id pub-id-type="pmid">36671042</pub-id></element-citation></ref><ref id="B58-medicina-59-00504"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marginean</surname><given-names>C.M.</given-names></name>
<name><surname>Cioboata</surname><given-names>R.</given-names></name>
<name><surname>Olteanu</surname><given-names>M.</given-names></name>
<name><surname>Vasile</surname><given-names>C.M.</given-names></name>
<name><surname>Popescu</surname><given-names>M.</given-names></name>
<name><surname>Popescu</surname><given-names>A.I.S.</given-names></name>
<name><surname>Bondari</surname><given-names>S.</given-names></name>
<name><surname>Pirscoveanu</surname><given-names>D.</given-names></name>
<name><surname>Marginean</surname><given-names>I.C.</given-names></name>
<name><surname>Iacob</surname><given-names>G.A.</given-names></name>
<etal/>
</person-group><article-title>The Importance of Accurate Early Diagnosis and Eradication in <italic toggle="yes">Helicobacter pylori</italic> Infection: Pictorial Summary Review in Children and Adults</article-title><source>Antibiotics</source><year>2022</year><volume>12</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12010060</pub-id><pub-id pub-id-type="pmid">36671261</pub-id></element-citation></ref><ref id="B59-medicina-59-00504"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>N.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Probiotic supplements are effective in people with cognitive impairment: A meta-analysis of randomized controlled trials</article-title><source>Nutr. Rev.</source><year>2023</year><fpage>nuac113</fpage><pub-id pub-id-type="doi">10.1093/nutrit/nuac113</pub-id><pub-id pub-id-type="pmid">36629438</pub-id></element-citation></ref><ref id="B60-medicina-59-00504"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>M.</given-names></name>
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Xi</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Qi</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>G.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>F.</given-names></name>
</person-group><article-title>School-based Hygiene Intervention to Prevent <italic toggle="yes">Helicobacter Pylori</italic> infection among childrEn (SHIP HOPE): Protocol for a cluster-randomised controlled trial</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e064207</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-064207</pub-id></element-citation></ref><ref id="B61-medicina-59-00504"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hern&#x000e1;ndez-V&#x000e1;squez</surname><given-names>A.</given-names></name>
<name><surname>Barrenechea-Pulache</surname><given-names>A.</given-names></name>
<name><surname>Aguirre-Ipenza</surname><given-names>R.</given-names></name>
<name><surname>Comand&#x000e9;</surname><given-names>D.</given-names></name>
<name><surname>Aza&#x000f1;edo</surname><given-names>D.</given-names></name>
</person-group><article-title>Interventions to Improve the Oral Hygiene of Individuals with Alzheimer&#x02019;s Disease: A Systematic Review</article-title><source>Dent. J.</source><year>2022</year><volume>10</volume><elocation-id>92</elocation-id><pub-id pub-id-type="doi">10.3390/dj10050092</pub-id></element-citation></ref><ref id="B62-medicina-59-00504"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>T.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Kountouras</surname><given-names>C.</given-names></name>
<name><surname>Arapoglou</surname><given-names>S.</given-names></name>
<name><surname>Exadaktylos</surname><given-names>A.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Tsolaki</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Impact of <italic toggle="yes">Helicobacter pylori</italic> and/or <italic toggle="yes">Helicobacter pylori</italic>-related metabolic syndrome on incidence of all-cause and Alzheimer&#x02019;s dementia</article-title><source>Alzheimer&#x02019;s Dement.</source><year>2019</year><volume>15</volume><fpage>723</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2019.01.008</pub-id><pub-id pub-id-type="pmid">30872115</pub-id></element-citation></ref><ref id="B63-medicina-59-00504"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>T.J.</given-names></name>
<name><surname>Song</surname><given-names>J.H.</given-names></name>
<name><surname>Jang</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Kang</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>H.R.</given-names></name>
<name><surname>Hwangbo</surname><given-names>S.</given-names></name>
<name><surname>Shin</surname><given-names>H.Y.</given-names></name>
<name><surname>Na</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Helicobacter Pylori</italic> Infection Is Associated with Neurodegeneration in Cognitively Normal Men</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2021</year><volume>82</volume><fpage>1591</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.3233/JAD-210119</pub-id><pub-id pub-id-type="pmid">34180413</pub-id></element-citation></ref><ref id="B64-medicina-59-00504"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>T.C.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> and Gastric Cancer</article-title><source>Gastrointest. Endosc. Clin.</source><year>2021</year><volume>31</volume><fpage>451</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.giec.2021.03.003</pub-id><pub-id pub-id-type="pmid">34053633</pub-id></element-citation></ref><ref id="B65-medicina-59-00504"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotera</surname><given-names>T.</given-names></name>
<name><surname>Nishimi</surname><given-names>Y.</given-names></name>
<name><surname>Kushima</surname><given-names>R.</given-names></name>
<name><surname>Haruma</surname><given-names>K.</given-names></name>
</person-group><article-title>Regression of Autoimmune Gastritis after Eradication of <italic toggle="yes">Helicobacter pylori</italic></article-title><source>Case Rep. Gastroenterol.</source><year>2023</year><volume>17</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1159/000528388</pub-id><pub-id pub-id-type="pmid">36742095</pub-id></element-citation></ref><ref id="B66-medicina-59-00504"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zeglinas</surname><given-names>C.</given-names></name>
<name><surname>Tzivras</surname><given-names>D.</given-names></name>
<name><surname>Romiopoulos</surname><given-names>I.</given-names></name>
<name><surname>Giorgakis</surname><given-names>N.</given-names></name>
<name><surname>Anastasiadou</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The Emerging Role of <italic toggle="yes">Helicobacter Pylori</italic>-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration</article-title><source>Curr. Mol. Med.</source><year>2017</year><volume>17</volume><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.2174/1566524018666171219094837</pub-id><pub-id pub-id-type="pmid">29256351</pub-id></element-citation></ref><ref id="B67-medicina-59-00504"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dardiotis</surname><given-names>E.</given-names></name>
<name><surname>Tsouris</surname><given-names>Z.</given-names></name>
<name><surname>Mentis</surname><given-names>A.-F.A.</given-names></name>
<name><surname>Siokas</surname><given-names>V.</given-names></name>
<name><surname>Michalopoulou</surname><given-names>A.</given-names></name>
<name><surname>Sokratous</surname><given-names>M.</given-names></name>
<name><surname>Dastamani</surname><given-names>M.</given-names></name>
<name><surname>Bogdanos</surname><given-names>D.P.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title><italic toggle="yes">H. pylori</italic> and Parkinson&#x02019;s disease: Meta-analyses including clinical severity</article-title><source>Clin. Neurol. Neurosurg.</source><year>2018</year><volume>175</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2018.09.039</pub-id><pub-id pub-id-type="pmid">30308319</pub-id></element-citation></ref><ref id="B68-medicina-59-00504"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lolekha</surname><given-names>P.</given-names></name>
<name><surname>Sriphanom</surname><given-names>T.</given-names></name>
<name><surname>Vilaichone</surname><given-names>R.-K.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> eradication improves motor fluctuations in advanced Parkinson&#x02019;s disease patients: A prospective cohort study (HP-PD trial)</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0251042</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0251042</pub-id><pub-id pub-id-type="pmid">33945559</pub-id></element-citation></ref><ref id="B69-medicina-59-00504"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Zhou</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>W.F.</given-names></name>
<name><surname>Yin</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>G.</given-names></name>
<name><surname>Ren</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Cortical atrophy is associated with cognitive impairment in Parkinson&#x02019;s disease: A combined analysis of cortical thickness and functional connectivity</article-title><source>Brain Imaging Behav.</source><year>2022</year><volume>16</volume><fpage>2586</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1007/s11682-022-00714-w</pub-id><pub-id pub-id-type="pmid">36044168</pub-id></element-citation></ref><ref id="B70-medicina-59-00504"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Shu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
</person-group><article-title>Exploring brain changes of impulse control disorders in Parkinson&#x02019;s disease: An ALE study</article-title><source>Front. Aging Neurosci.</source><year>2022</year><volume>14</volume><fpage>966525</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.966525</pub-id><pub-id pub-id-type="pmid">36110428</pub-id></element-citation></ref><ref id="B71-medicina-59-00504"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Mylopoulos</surname><given-names>N.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Boura</surname><given-names>P.</given-names></name>
<name><surname>Konstas</surname><given-names>A.G.P.</given-names></name>
<name><surname>Venizelos</surname><given-names>J.</given-names></name>
</person-group><article-title>Eradication of <italic toggle="yes">Helicobacter pylori</italic> May Be Beneficial in the Management of Chronic Open-Angle Glaucoma</article-title><source>Arch. Intern Med.</source><year>2002</year><volume>162</volume><fpage>1237</fpage><pub-id pub-id-type="doi">10.1001/archinte.162.11.1237</pub-id><pub-id pub-id-type="pmid">12038941</pub-id></element-citation></ref><ref id="B72-medicina-59-00504"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>M.C.</given-names></name>
<name><surname>Conner</surname><given-names>I.P.</given-names></name>
<name><surname>Teng</surname><given-names>C.Y.</given-names></name>
<name><surname>Lawrence</surname><given-names>J.D.</given-names></name>
<name><surname>Safiullah</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Bilonick</surname><given-names>R.A.</given-names></name>
<name><surname>Kim</surname><given-names>S.G.</given-names></name>
<name><surname>Wollstein</surname><given-names>G.</given-names></name>
<name><surname>Schuman</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Retinal Structures and Visual Cortex Activity are Impaired Prior to Clinical Vision Loss in Glaucoma</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>31464</fpage><pub-id pub-id-type="doi">10.1038/srep31464</pub-id><pub-id pub-id-type="pmid">27510406</pub-id></element-citation></ref><ref id="B73-medicina-59-00504"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Dai</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>B.</given-names></name>
<name><surname>Liang</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><article-title>Progressive Thinning of Visual Cortex in Primary Open-Angle Glaucoma of Varying Severity</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0121960</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0121960</pub-id><pub-id pub-id-type="pmid">25816070</pub-id></element-citation></ref><ref id="B74-medicina-59-00504"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>M.L.</given-names></name>
<name><surname>Chen</surname><given-names>J.H.</given-names></name>
<name><surname>Tsai</surname><given-names>M.K.</given-names></name>
<name><surname>Liou</surname><given-names>J.M.</given-names></name>
<name><surname>Chiou</surname><given-names>J.M.</given-names></name>
<name><surname>Chiu</surname><given-names>M.J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Association between <italic toggle="yes">Helicobacter pylori</italic> infection and cognitive impairment in the elderly</article-title><source>J. Formos. Med. Assoc.</source><year>2018</year><volume>117</volume><fpage>994</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2017.11.005</pub-id><pub-id pub-id-type="pmid">29175144</pub-id></element-citation></ref><ref id="B75-medicina-59-00504"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prevete</surname><given-names>N.</given-names></name>
<name><surname>Rossi</surname><given-names>F.W.</given-names></name>
<name><surname>Rivellese</surname><given-names>F.</given-names></name>
<name><surname>Lamacchia</surname><given-names>D.</given-names></name>
<name><surname>Pelosi</surname><given-names>C.</given-names></name>
<name><surname>Lobasso</surname><given-names>A.</given-names></name>
<name><surname>Necchi</surname><given-names>V.</given-names></name>
<name><surname>Solcia</surname><given-names>E.</given-names></name>
<name><surname>Fiocca</surname><given-names>R.</given-names></name>
<name><surname>Ceppa</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> HP(2&#x02013;20) Induces Eosinophil Activation and Accumulation in Superficial Gastric Mucosa and Stimulates VEGF-&#x003b1; and TGF-&#x003b2; Release by Interacting with Formyl-Peptide Receptors</article-title><source>Int. J. Immunopathol. Pharmacol.</source><year>2013</year><volume>26</volume><fpage>647</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1177/039463201302600308</pub-id><pub-id pub-id-type="pmid">24067461</pub-id></element-citation></ref><ref id="B76-medicina-59-00504"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.L.</given-names></name>
<name><surname>Zeng</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>J.</given-names></name>
<name><surname>Tian</surname><given-names>Y.T.</given-names></name>
<name><surname>Liu</surname><given-names>Y.J.</given-names></name>
<name><surname>Qiu</surname><given-names>M.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Xiong</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.H.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> filtrate impairs spatial learning and memory in rats and increases &#x000ce;<sup>2</sup>-amyloid by enhancing expression of presenilin-2</article-title><source>Front. Aging Neurosci.</source><year>2014</year><volume>6</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2014.00066</pub-id><pub-id pub-id-type="pmid">24782763</pub-id></element-citation></ref><ref id="B77-medicina-59-00504"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berrett</surname><given-names>A.N.</given-names></name>
<name><surname>Gale</surname><given-names>S.D.</given-names></name>
<name><surname>Erickson</surname><given-names>L.D.</given-names></name>
<name><surname>Brown</surname><given-names>B.L.</given-names></name>
<name><surname>Hedges</surname><given-names>D.W.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> moderates the association between 5-MTHF concentration and cognitive function in older adults</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0190475</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0190475</pub-id><pub-id pub-id-type="pmid">29364915</pub-id></element-citation></ref><ref id="B78-medicina-59-00504"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bu</surname><given-names>X.L.</given-names></name>
<name><surname>Yao</surname><given-names>X.Q.</given-names></name>
<name><surname>Jiao</surname><given-names>S.S.</given-names></name>
<name><surname>Zeng</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>Y.H.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Xiang</surname><given-names>C.R.</given-names></name>
<name><surname>Liang</surname><given-names>Q.H.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.Y.</given-names></name>
<etal/>
</person-group><article-title>A study on the association between infectious burden and Alzheimer&#x02019;s disease</article-title><source>Eur. J. Neurol.</source><year>2015</year><volume>22</volume><fpage>1519</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1111/ene.12477</pub-id><pub-id pub-id-type="pmid">24910016</pub-id></element-citation></ref><ref id="B79-medicina-59-00504"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katsinelos</surname><given-names>T.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Molecular Links Between Alzheimer&#x02019;s Disease and Gastrointestinal Microbiota: Emphasis on <italic toggle="yes">Helicobacter pylori</italic> Infection Involvement</article-title><source>Curr. Mol. Med.</source><year>2019</year><volume>20</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2174/1566524019666190917125917</pub-id><pub-id pub-id-type="pmid">31530263</pub-id></element-citation></ref><ref id="B80-medicina-59-00504"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>N.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Potential impact of <italic toggle="yes">Helicobacter pylori</italic>-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis</article-title><source>Dig. Liver Dis.</source><year>2020</year><volume>52</volume><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2019.09.001</pub-id><pub-id pub-id-type="pmid">31629704</pub-id></element-citation></ref><ref id="B81-medicina-59-00504"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Bakirtzis</surname><given-names>C.</given-names></name>
<name><surname>Sintila</surname><given-names>S.-A.</given-names></name>
<name><surname>Touloumtzi</surname><given-names>M.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>N.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Potential impact of <italic toggle="yes">Helicobacter pylori</italic>-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders</article-title><source>Metabolism</source><year>2021</year><volume>118</volume><fpage>154736</fpage><pub-id pub-id-type="doi">10.1016/j.metabol.2021.154736</pub-id><pub-id pub-id-type="pmid">33636167</pub-id></element-citation></ref><ref id="B82-medicina-59-00504"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xie</surname><given-names>J.</given-names></name>
<name><surname>Cools</surname><given-names>L.</given-names></name>
<name><surname>van Imschoot</surname><given-names>G.</given-names></name>
<name><surname>van Wonterghem</surname><given-names>E.</given-names></name>
<name><surname>Pauwels</surname><given-names>M.J.</given-names></name>
<name><surname>Vlaeminck</surname><given-names>I.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic>-derived outer membrane vesicles contribute to Alzheimer&#x02019;s disease pathogenesis via C3-C3aR signalling</article-title><source>J. Extracell. Vesicles</source><year>2023</year><volume>12</volume><fpage>12306</fpage><pub-id pub-id-type="doi">10.1002/jev2.12306</pub-id><pub-id pub-id-type="pmid">36792546</pub-id></element-citation></ref><ref id="B83-medicina-59-00504"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<name><surname>Ojetti</surname><given-names>V.</given-names></name>
<name><surname>Candelli</surname><given-names>M.</given-names></name>
<name><surname>Covino</surname><given-names>M.</given-names></name>
<name><surname>Cardone</surname><given-names>S.</given-names></name>
<name><surname>Potenza</surname><given-names>A.</given-names></name>
<name><surname>Simeoni</surname><given-names>B.</given-names></name>
<name><surname>Gabrielli</surname><given-names>M.</given-names></name>
<name><surname>Sabia</surname><given-names>L.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Microbes and Alzheimer&#x02019; disease: Lessons from H. pylori and GUT microbiota</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2019</year><volume>23</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201901_16791</pub-id><pub-id pub-id-type="pmid">30657587</pub-id></element-citation></ref><ref id="B84-medicina-59-00504"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llado-Saz</surname><given-names>S.</given-names></name>
<name><surname>Atienza</surname><given-names>M.</given-names></name>
<name><surname>Cantero</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects</article-title><source>Neurobiol. Aging</source><year>2015</year><volume>36</volume><fpage>2791</fpage><lpage>2797</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.06.023</pub-id><pub-id pub-id-type="pmid">26182906</pub-id></element-citation></ref><ref id="B85-medicina-59-00504"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade-Guerrero</surname><given-names>J.</given-names></name>
<name><surname>Santiago-Balmaseda</surname><given-names>A.</given-names></name>
<name><surname>Jeronimo-Aguilar</surname><given-names>P.</given-names></name>
<name><surname>Vargas-Rodr&#x000ed;guez</surname><given-names>I.</given-names></name>
<name><surname>Cadena-Su&#x000e1;rez</surname><given-names>A.R.</given-names></name>
<name><surname>S&#x000e1;nchez-Garibay</surname><given-names>C.</given-names></name>
<name><surname>Molina</surname><given-names>G.P.</given-names></name>
<name><surname>M&#x000e9;ndez-Catal&#x000e1;</surname><given-names>C.F.</given-names></name>
<name><surname>Delnas-Aguayo</surname><given-names>M.d.C.</given-names></name>
<name><surname>Diaz-Cintra</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Alzheimer&#x02019;s Disease: An Updated Overview of Its Genetics</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>3754</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24043754</pub-id><pub-id pub-id-type="pmid">36835161</pub-id></element-citation></ref><ref id="B86-medicina-59-00504"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Roeck</surname><given-names>A.</given-names></name>
<name><surname>van Broeckhoven</surname><given-names>C.</given-names></name>
<name><surname>Sleegers</surname><given-names>K.</given-names></name>
</person-group><article-title>The role of ABCA7 in Alzheimer&#x02019;s disease: Evidence from genomics, transcriptomics and methylomics</article-title><source>Acta Neuropathol.</source><year>2019</year><volume>138</volume><fpage>201</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00401-019-01994-1</pub-id><pub-id pub-id-type="pmid">30903345</pub-id></element-citation></ref><ref id="B87-medicina-59-00504"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Narayan</surname><given-names>P.</given-names></name>
<name><surname>Sienski</surname><given-names>G.</given-names></name>
<name><surname>Bonner</surname><given-names>J.M.</given-names></name>
<name><surname>Lin</surname><given-names>Y.-T.</given-names></name>
<name><surname>Seo</surname><given-names>J.</given-names></name>
<name><surname>Baru</surname><given-names>V.</given-names></name>
<name><surname>Haque</surname><given-names>A.</given-names></name>
<name><surname>Milo</surname><given-names>B.</given-names></name>
<name><surname>Akay</surname><given-names>L.A.</given-names></name>
<name><surname>Graziosi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>PICALM Rescues Endocytic Defects Caused by the Alzheimer&#x02019;s Disease Risk Factor APOE4</article-title><source>Cell Rep</source><year>2020</year><volume>33</volume><fpage>108224</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108224</pub-id><pub-id pub-id-type="pmid">33027662</pub-id></element-citation></ref><ref id="B88-medicina-59-00504"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uddin</surname><given-names>M.S.</given-names></name>
<name><surname>Kabir</surname><given-names>M.T.</given-names></name>
<name><surname>Begum</surname><given-names>M.M.</given-names></name>
<name><surname>Islam</surname><given-names>M.S.</given-names></name>
<name><surname>Behl</surname><given-names>T.</given-names></name>
<name><surname>Ashraf</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Correction to: Exploring the Role of CLU in the Pathogenesis of Alzheimer&#x02019;s Disease</article-title><source>Neurotox. Res.</source><year>2020</year><volume>38</volume><fpage>1062</fpage><pub-id pub-id-type="doi">10.1007/s12640-020-00279-w</pub-id><pub-id pub-id-type="pmid">32860614</pub-id></element-citation></ref><ref id="B89-medicina-59-00504"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stage</surname><given-names>E.</given-names></name>
<name><surname>Duran</surname><given-names>T.</given-names></name>
<name><surname>Risacher</surname><given-names>S.L.</given-names></name>
<name><surname>Goukasian</surname><given-names>N.</given-names></name>
<name><surname>Do</surname><given-names>T.M.</given-names></name>
<name><surname>West</surname><given-names>J.D.</given-names></name>
<name><surname>Wilhalme</surname><given-names>H.</given-names></name>
<name><surname>Nho</surname><given-names>K.</given-names></name>
<name><surname>Phillips</surname><given-names>M.</given-names></name>
<name><surname>Elashoff</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism</article-title><source>Alzheimer&#x02019;s Dement. Diagn. Assess. Dis. Monit.</source><year>2016</year><volume>5</volume><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2016.12.003</pub-id></element-citation></ref><ref id="B90-medicina-59-00504"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tesi</surname><given-names>N.</given-names></name>
<name><surname>van der Lee</surname><given-names>S.J.</given-names></name>
<name><surname>Hulsman</surname><given-names>M.</given-names></name>
<name><surname>Jansen</surname><given-names>I.E.</given-names></name>
<name><surname>Stringa</surname><given-names>N.</given-names></name>
<name><surname>van Schoor</surname><given-names>N.</given-names></name>
<name><surname>Meijers-Heijboer</surname><given-names>H.</given-names></name>
<name><surname>Huisman</surname><given-names>M.</given-names></name>
<name><surname>Scheltens</surname><given-names>P.</given-names></name>
<name><surname>Reinders</surname><given-names>M.J.T.</given-names></name>
<etal/>
</person-group><article-title>Centenarian controls increase variant effect sizes by an average twofold in an extreme case&#x02013;extreme control analysis of Alzheimer&#x02019;s disease</article-title><source>Eur. J. Hum. Genet.</source><year>2019</year><volume>27</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/s41431-018-0273-5</pub-id><pub-id pub-id-type="pmid">30258121</pub-id></element-citation></ref><ref id="B91-medicina-59-00504"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>You</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>W.</given-names></name>
<name><surname>Wan</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>The Influence of MTHFR Polymorphism on Gray Matter Volume in Patients with Amnestic Mild Cognitive Impairment</article-title><source>Front. Neurosci.</source><year>2021</year><volume>15</volume><fpage>778123</fpage><pub-id pub-id-type="doi">10.3389/fnins.2021.778123</pub-id><pub-id pub-id-type="pmid">34916904</pub-id></element-citation></ref><ref id="B92-medicina-59-00504"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><article-title>The common genes involved in the pathogenesis of Alzheimer&#x02019;s disease and type 2 diabetes and their implication for drug repositioning</article-title><source>Neuropharmacology</source><year>2023</year><volume>223</volume><fpage>109327</fpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109327</pub-id><pub-id pub-id-type="pmid">36368623</pub-id></element-citation></ref><ref id="B93-medicina-59-00504"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cajavilca</surname><given-names>C.E.</given-names></name>
<name><surname>Gadhia</surname><given-names>R.R.</given-names></name>
<name><surname>Rom&#x000e1;n</surname><given-names>G.C.</given-names></name>
</person-group><article-title>MTHFR Gene Mutations Correlate with White Matter Disease Burden and Predict Cerebrovascular Disease and Dementia</article-title><source>Brain Sci.</source><year>2019</year><volume>9</volume><elocation-id>211</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci9090211</pub-id><pub-id pub-id-type="pmid">31443445</pub-id></element-citation></ref><ref id="B94-medicina-59-00504"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kara</surname><given-names>I.</given-names></name>
<name><surname>Sazci</surname><given-names>A.</given-names></name>
<name><surname>Ergul</surname><given-names>E.</given-names></name>
<name><surname>Kaya</surname><given-names>G.</given-names></name>
<name><surname>Kilic</surname><given-names>G.</given-names></name>
</person-group><article-title>Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk</article-title><source>Mol. Brain Res.</source><year>2003</year><volume>111</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0169-328X(02)00672-1</pub-id><pub-id pub-id-type="pmid">12654508</pub-id></element-citation></ref><ref id="B95-medicina-59-00504"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Laws</surname><given-names>S.M.</given-names></name>
<name><surname>Miles</surname><given-names>L.A.</given-names></name>
<name><surname>Wiley</surname><given-names>J.S.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Masters</surname><given-names>C.L.</given-names></name>
<name><surname>Gu</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Genomics of Alzheimer&#x02019;s disease implicates the innate and adaptive immune systems</article-title><source>Cell. Mol. Life Sci.</source><year>2021</year><volume>78</volume><fpage>7397</fpage><lpage>7426</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03986-5</pub-id><pub-id pub-id-type="pmid">34708251</pub-id></element-citation></ref><ref id="B96-medicina-59-00504"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12&#x02013;folate deficiency, and hyperhomocysteinemia sequence</article-title><source>Am. J. Clin. Nutr.</source><year>2007</year><volume>86</volume><fpage>805</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1093/ajcn/86.3.805</pub-id><pub-id pub-id-type="pmid">17823449</pub-id></element-citation></ref><ref id="B97-medicina-59-00504"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santarelli</surname><given-names>L.</given-names></name>
<name><surname>Gabrielli</surname><given-names>M.</given-names></name>
<name><surname>Cremonini</surname><given-names>F.</given-names></name>
<name><surname>Santoliquido</surname><given-names>A.</given-names></name>
<name><surname>Candelli</surname><given-names>M.</given-names></name>
<name><surname>Nista</surname><given-names>E.C.</given-names></name>
<name><surname>Pola</surname><given-names>P.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>G.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>A.</given-names></name>
</person-group><article-title>Atrophic gastritis as a cause of hyperhomocysteinaemia</article-title><source>Aliment. Pharmacol. Ther.</source><year>2004</year><volume>19</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01820.x</pub-id><pub-id pub-id-type="pmid">14687172</pub-id></element-citation></ref><ref id="B98-medicina-59-00504"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasan</surname><given-names>T.</given-names></name>
<name><surname>Arora</surname><given-names>R.</given-names></name>
<name><surname>Bansal</surname><given-names>A.K.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>G.S.</given-names></name>
<name><surname>Singh</surname><given-names>L.R.</given-names></name>
</person-group><article-title>Disturbed homocysteine metabolism is associated with cancer</article-title><source>Exp. Mol. Med.</source><year>2019</year><volume>51</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s12276-019-0216-4</pub-id></element-citation></ref><ref id="B99-medicina-59-00504"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCully</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Homocysteine Metabolism, Atherosclerosis, and Diseases of Aging</article-title><source>Compr. Physiol.</source><year>2015</year><volume>6</volume><fpage>471</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1002/cphy.c150021</pub-id><pub-id pub-id-type="pmid">26756640</pub-id></element-citation></ref><ref id="B100-medicina-59-00504"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Zeglinas</surname><given-names>C.</given-names></name>
<name><surname>Artemaki</surname><given-names>F.</given-names></name>
<name><surname>Tzivras</surname><given-names>D.</given-names></name>
<name><surname>Vardaka</surname><given-names>E.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Romiopoulos</surname><given-names>I.</given-names></name>
<name><surname>Symeonidou</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Cardio-cerebrovascular disease and <italic toggle="yes">Helicobacter pylori</italic>-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy</article-title><source>Int. J. Cardiol.</source><year>2017</year><volume>229</volume><fpage>17</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.11.265</pub-id><pub-id pub-id-type="pmid">27887801</pub-id></element-citation></ref><ref id="B101-medicina-59-00504"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bostom</surname><given-names>A.G.</given-names></name>
<name><surname>Shemin</surname><given-names>D.</given-names></name>
<name><surname>Lapane</surname><given-names>K.L.</given-names></name>
<name><surname>Sutherland</surname><given-names>P.</given-names></name>
<name><surname>Nadeau</surname><given-names>M.R.</given-names></name>
<name><surname>Wilson</surname><given-names>P.W.F.</given-names></name>
<name><surname>Yoburn</surname><given-names>D.</given-names></name>
<name><surname>Bausserman</surname><given-names>L.</given-names></name>
<name><surname>Tofler</surname><given-names>G.</given-names></name>
<name><surname>Jacques</surname><given-names>P.F.</given-names></name>
<etal/>
</person-group><article-title>Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study</article-title><source>Atherosclerosis</source><year>1996</year><volume>125</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/0021-9150(96)05865-0</pub-id><pub-id pub-id-type="pmid">8831931</pub-id></element-citation></ref><ref id="B102-medicina-59-00504"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rom&#x000e1;n</surname><given-names>G.C.</given-names></name>
</person-group><article-title>Vascular dementia prevention: A risk factor analysis</article-title><source>Cerebrovasc. Dis.</source><year>2005</year><volume>20</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1159/000089361</pub-id><pub-id pub-id-type="pmid">16327258</pub-id></element-citation></ref><ref id="B103-medicina-59-00504"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nieraad</surname><given-names>H.</given-names></name>
<name><surname>de Bruin</surname><given-names>N.</given-names></name>
<name><surname>Arne</surname><given-names>O.</given-names></name>
<name><surname>Hofmann</surname><given-names>M.C.J.</given-names></name>
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
<name><surname>Saito</surname><given-names>T.</given-names></name>
<name><surname>Saido</surname><given-names>T.C.</given-names></name>
<name><surname>Gurke</surname><given-names>R.</given-names></name>
<name><surname>Schmidt</surname><given-names>D.</given-names></name>
<name><surname>Till</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Impact of Hyperhomocysteinemia and Different Dietary Interventions on Cognitive Performance in a Knock-in Mouse Model for Alzheimer&#x02019;s Disease</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>3248</elocation-id><pub-id pub-id-type="doi">10.3390/nu12113248</pub-id><pub-id pub-id-type="pmid">33114054</pub-id></element-citation></ref><ref id="B104-medicina-59-00504"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prats-Soteras</surname><given-names>X.</given-names></name>
<name><surname>Jurado</surname><given-names>M.A.</given-names></name>
<name><surname>Ottino-Gonz&#x000e1;lez</surname><given-names>J.</given-names></name>
<name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>I.</given-names></name>
<name><surname>Segura</surname><given-names>B.</given-names></name>
<name><surname>Cald&#x000fa;</surname><given-names>X.</given-names></name>
<name><surname>S&#x000e1;nchez-Garre</surname><given-names>C.</given-names></name>
<name><surname>Mir&#x000f3;</surname><given-names>N.</given-names></name>
<name><surname>Tor</surname><given-names>C.</given-names></name>
<name><surname>Sender-Palacios</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Inflammatory agents partially explain associations between cortical thickness, surface area, and body mass in adolescents and young adulthood</article-title><source>Int. J. Obes.</source><year>2020</year><volume>44</volume><fpage>1487</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1038/s41366-020-0582-y</pub-id><pub-id pub-id-type="pmid">32433603</pub-id></element-citation></ref><ref id="B105-medicina-59-00504"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>B.</given-names></name>
<name><surname>Venketasubramanian</surname><given-names>N.</given-names></name>
<name><surname>Vrooman</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>C.Y.</given-names></name>
<name><surname>Wong</surname><given-names>T.Y.</given-names></name>
<name><surname>Ikram</surname><given-names>M.K.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Saima</surname><given-names>H.</given-names></name>
</person-group><article-title>Homocysteine and Cerebral Atrophy: The Epidemiology of Dementia in Singapore Study</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2018</year><volume>62</volume><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.3233/JAD-170796</pub-id><pub-id pub-id-type="pmid">29480177</pub-id></element-citation></ref><ref id="B106-medicina-59-00504"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Huo</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>G.</given-names></name>
</person-group><article-title>Morphological Changes in Cortical and Subcortical Structures in Multiple System Atrophy Patients with Mild Cognitive Impairment</article-title><source>Front. Hum. Neurosci.</source><year>2021</year><volume>15</volume><fpage>649051</fpage><pub-id pub-id-type="doi">10.3389/fnhum.2021.649051</pub-id><pub-id pub-id-type="pmid">33833672</pub-id></element-citation></ref><ref id="B107-medicina-59-00504"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>di Meco</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>J.G.</given-names></name>
<name><surname>Pratic&#x000f2;</surname><given-names>D.</given-names></name>
</person-group><article-title>Dissecting the Role of 5-Lipoxygenase in the Homocysteine-Induced Alzheimer&#x02019;s Disease Pathology</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2018</year><volume>62</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.3233/JAD-170700</pub-id><pub-id pub-id-type="pmid">29254095</pub-id></element-citation></ref><ref id="B108-medicina-59-00504"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Boziki</surname><given-names>M.</given-names></name>
<name><surname>Gavalas</surname><given-names>E.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Deretzi</surname><given-names>G.</given-names></name>
<name><surname>Chatzigeorgiou</surname><given-names>S.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Grigoriadis</surname><given-names>N.</given-names></name>
<name><surname>Giartza-Taxidou</surname><given-names>E.</given-names></name>
<name><surname>Venizelos</surname><given-names>I.</given-names></name>
</person-group><article-title>Five-year survival after <italic toggle="yes">Helicobacter pylori</italic> eradication in Alzheimer disease patients</article-title><source>Cogn. Behav. Neurol.</source><year>2010</year><volume>23</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1097/WNN.0b013e3181df3034</pub-id><pub-id pub-id-type="pmid">20829670</pub-id></element-citation></ref><ref id="B109-medicina-59-00504"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
</person-group><article-title>Persistent <italic toggle="yes">Helicobacter pylori</italic> infection for more than 3 years leads to elevated serum homocysteine concentration: A retrospective cohort study based on a healthy Chinese population</article-title><source>J. Gastroenterol. Hepatol.</source><year>2021</year><volume>36</volume><fpage>3077</fpage><lpage>3083</lpage><pub-id pub-id-type="doi">10.1111/jgh.15603</pub-id><pub-id pub-id-type="pmid">34198362</pub-id></element-citation></ref><ref id="B110-medicina-59-00504"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marino</surname><given-names>M.C.A.</given-names></name>
<name><surname>de Oliveira</surname><given-names>C.A.</given-names></name>
<name><surname>Rocha</surname><given-names>A.M.C.</given-names></name>
<name><surname>Rocha</surname><given-names>G.A.</given-names></name>
<name><surname>Clementino</surname><given-names>N.C.D.</given-names></name>
<name><surname>Antunes</surname><given-names>L.F.</given-names></name>
<name><surname>Oliveira</surname><given-names>R.A.</given-names></name>
<name><surname>Martins</surname><given-names>A.S.</given-names></name>
<name><surname>Del Puerto</surname><given-names>H.L.</given-names></name>
<name><surname>D&#x02019;Almeida</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Long-term effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on plasma homocysteine in elderly patients with cobalamin deficiency</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1136/gut.2006.095125</pub-id><pub-id pub-id-type="pmid">17005765</pub-id></element-citation></ref><ref id="B111-medicina-59-00504"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Extragastric Diseases and <italic toggle="yes">Helicobacter pylori</italic></article-title><source>Helicobacter</source><year>2015</year><volume>20</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/hel.12256</pub-id><pub-id pub-id-type="pmid">26372824</pub-id></element-citation></ref><ref id="B112-medicina-59-00504"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chin</surname><given-names>K.S.</given-names></name>
<name><surname>Yassi</surname><given-names>N.</given-names></name>
<name><surname>Churilov</surname><given-names>L.</given-names></name>
<name><surname>Masters</surname><given-names>C.L.</given-names></name>
<name><surname>Watson</surname><given-names>R.</given-names></name>
</person-group><article-title>Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis</article-title><source>Park. Relat. Disord.</source><year>2020</year><volume>80</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.09.030</pub-id></element-citation></ref><ref id="B113-medicina-59-00504"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sohrabi</surname><given-names>T.</given-names></name>
<name><surname>Mirzaei-Behbahani</surname><given-names>B.</given-names></name>
<name><surname>Zadali</surname><given-names>R.</given-names></name>
<name><surname>Pirhaghi</surname><given-names>M.</given-names></name>
<name><surname>Morozova-Roche</surname><given-names>L.A.</given-names></name>
<name><surname>Meratan</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Common Mechanisms Underlying &#x003b1;-Synuclein-Induced Mitochondrial Dysfunction in Parkinson&#x02019;s Disease</article-title><source>J. Mol. Biol.</source><year>2023</year><fpage>167992</fpage><pub-id pub-id-type="doi">10.1016/j.jmb.2023.167992</pub-id><pub-id pub-id-type="pmid">36736886</pub-id></element-citation></ref><ref id="B114-medicina-59-00504"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosca</surname><given-names>E.</given-names></name>
<name><surname>Simu</surname><given-names>M.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson&#x02019;s Disease: A Systematic Review</article-title><source>Brain Sci.</source><year>2020</year><volume>10</volume><elocation-id>588</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci10090588</pub-id><pub-id pub-id-type="pmid">32854426</pub-id></element-citation></ref><ref id="B115-medicina-59-00504"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.M.</given-names></name>
<name><surname>Koh</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Many Faces of Parkinson&#x02019;s Disease: Non-Motor Symptoms of Parkinson&#x02019;s Disease</article-title><source>J. Mov. Disord.</source><year>2015</year><volume>8</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.14802/jmd.15003</pub-id><pub-id pub-id-type="pmid">26090081</pub-id></element-citation></ref><ref id="B116-medicina-59-00504"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rong</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Nie</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Cai</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Meynert nucleus-related cortical thinning in Parkinson&#x02019;s disease with mild cognitive impairment</article-title><source>Quant. Imaging Med. Surg.</source><year>2021</year><volume>11</volume><fpage>1554</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.21037/qims-20-444</pub-id><pub-id pub-id-type="pmid">33816191</pub-id></element-citation></ref><ref id="B117-medicina-59-00504"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>E.J.</given-names></name>
<name><surname>Monchi</surname><given-names>O.</given-names></name>
</person-group><article-title>Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson&#x02019;s disease</article-title><source>NPJ Park. Dis.</source><year>2021</year><volume>7</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1038/s41531-021-00164-z</pub-id></element-citation></ref><ref id="B118-medicina-59-00504"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>H.</given-names></name>
<name><surname>Niccolini</surname><given-names>F.</given-names></name>
<name><surname>Pellicano</surname><given-names>C.</given-names></name>
<name><surname>Politis</surname><given-names>M.</given-names></name>
</person-group><article-title>Cortical thinning across Parkinson&#x02019;s disease stages and clinical correlates</article-title><source>J. Neurol. Sci.</source><year>2019</year><volume>398</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2019.01.020</pub-id><pub-id pub-id-type="pmid">30682518</pub-id></element-citation></ref><ref id="B119-medicina-59-00504"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uribe</surname><given-names>C.</given-names></name>
<name><surname>Segura</surname><given-names>B.</given-names></name>
<name><surname>Baggio</surname><given-names>H.C.</given-names></name>
<name><surname>Abos</surname><given-names>A.</given-names></name>
<name><surname>Garcia-Diaz</surname><given-names>A.I.</given-names></name>
<name><surname>Campabadal</surname><given-names>A.</given-names></name>
<name><surname>Marti</surname><given-names>M.J.</given-names></name>
<name><surname>Valldeoriola</surname><given-names>F.</given-names></name>
<name><surname>Compta</surname><given-names>Y.</given-names></name>
<name><surname>Bargallo</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Progression of Parkinson&#x02019;s disease patients&#x02019; subtypes based on cortical thinning: 4-year follow-up</article-title><source>Park. Relat. Disord.</source><year>2019</year><volume>64</volume><fpage>286</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2019.05.012</pub-id></element-citation></ref><ref id="B120-medicina-59-00504"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>P.</given-names></name>
<name><surname>Gao</surname><given-names>M.</given-names></name>
<name><surname>Yung</surname><given-names>K.K.L.</given-names></name>
</person-group><article-title>Association of Intestinal Disorders with Parkinson&#x02019;s Disease and Alzheimer&#x02019;s Disease: A Systematic Review and Meta-Analysis</article-title><source>ACS Chem. Neurosci.</source><year>2020</year><volume>11</volume><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.9b00607</pub-id><pub-id pub-id-type="pmid">31876406</pub-id></element-citation></ref><ref id="B121-medicina-59-00504"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGee</surname><given-names>D.J.</given-names></name>
<name><surname>Lu</surname><given-names>X.-H.</given-names></name>
<name><surname>Disbrow</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Stomaching the Possibility of a Pathogenic Role for <italic toggle="yes">Helicobacter pylori</italic> in Parkinson&#x02019;s Disease</article-title><source>J. Park. Dis.</source><year>2018</year><volume>8</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.3233/JPD-181327</pub-id></element-citation></ref><ref id="B122-medicina-59-00504"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fan</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Qi</surname><given-names>G.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
</person-group><article-title>Role of homocysteine in the development and progression of Parkinson&#x02019;s disease</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2020</year><volume>7</volume><fpage>2332</fpage><lpage>2338</lpage><pub-id pub-id-type="doi">10.1002/acn3.51227</pub-id><pub-id pub-id-type="pmid">33085841</pub-id></element-citation></ref><ref id="B123-medicina-59-00504"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sampedro</surname><given-names>F.</given-names></name>
<name><surname>Mart&#x000ed;nez-Horta</surname><given-names>S.</given-names></name>
<name><surname>Horta-Barba</surname><given-names>A.</given-names></name>
<name><surname>Grothe</surname><given-names>M.J.</given-names></name>
<name><surname>Labrador-Espinosa</surname><given-names>M.A.</given-names></name>
<name><surname>Jes&#x000fa;s</surname><given-names>S.</given-names></name>
<name><surname>G&#x000f3;mez</surname><given-names>A.A.</given-names></name>
<name><surname>Carrillo</surname><given-names>F.</given-names></name>
<name><surname>Puig-Davi</surname><given-names>A.</given-names></name>
<name><surname>Rold&#x000e1;n Lora</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Increased homocysteine levels correlate with cortical structural damage in Parkinson&#x02019;s disease</article-title><source>J. Neurol. Sci.</source><year>2022</year><volume>434</volume><fpage>120148</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2022.120148</pub-id><pub-id pub-id-type="pmid">35085959</pub-id></element-citation></ref><ref id="B124-medicina-59-00504"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peri&#x000f1;&#x000e1;n</surname><given-names>M.T.</given-names></name>
<name><surname>Mac&#x000ed;as-Garc&#x000ed;a</surname><given-names>D.</given-names></name>
<name><surname>Jes&#x000fa;s</surname><given-names>S.</given-names></name>
<name><surname>Mart&#x000ed;n-Rodr&#x000ed;guez</surname><given-names>J.F.</given-names></name>
<name><surname>Mu&#x000f1;oz-Delgado</surname><given-names>L.</given-names></name>
<name><surname>Jimenez-Jaraba</surname><given-names>M.V.</given-names></name>
<name><surname>Buiza-Rueda</surname><given-names>D.</given-names></name>
<name><surname>Bonilla-Toribio</surname><given-names>M.</given-names></name>
<name><surname>Adarmes-G&#x000f3;mez</surname><given-names>A.D.</given-names></name>
<name><surname>G&#x000f3;mez-Garre</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Homocysteine levels, genetic background, and cognitive impairment in Parkinson&#x02019;s disease</article-title><source>J. Neurol.</source><year>2023</year><volume>270</volume><fpage>477</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s00415-022-11361-y</pub-id><pub-id pub-id-type="pmid">36169739</pub-id></element-citation></ref><ref id="B125-medicina-59-00504"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anamnart</surname><given-names>C.</given-names></name>
<name><surname>Kitjarak</surname><given-names>R.</given-names></name>
</person-group><article-title>Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson&#x02019;s disease patients: A randomized controlled study</article-title><source>J. Clin. Neurosci.</source><year>2021</year><volume>88</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2021.03.047</pub-id><pub-id pub-id-type="pmid">33992189</pub-id></element-citation></ref><ref id="B126-medicina-59-00504"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Czesnikiewicz-Guzik</surname><given-names>M.</given-names></name>
<name><surname>Bielanski</surname><given-names>W.</given-names></name>
<name><surname>Guzik</surname><given-names>T.J.</given-names></name>
<name><surname>Loster</surname><given-names>B.</given-names></name>
<name><surname>Konturek</surname><given-names>S.J.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic> in the oral cavity and its implications for gastric infection, periodontal health, immunology and dyspepsia</article-title><source>J. Physiol. Pharmacol.</source><year>2005</year><volume>6</volume><fpage>77</fpage><lpage>89</lpage></element-citation></ref><ref id="B127-medicina-59-00504"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>R.</given-names></name>
<name><surname>Xue</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>T.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>Q.</given-names></name>
</person-group><article-title>Periodontal disease and <italic toggle="yes">Helicobacter pylori</italic> infection in oral cavity: A meta-analysis of 2727 participants mainly based on Asian studies</article-title><source>Clin. Oral Investig.</source><year>2020</year><volume>24</volume><fpage>2175</fpage><lpage>2188</lpage><pub-id pub-id-type="doi">10.1007/s00784-020-03330-4</pub-id></element-citation></ref><ref id="B128-medicina-59-00504"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pisani</surname><given-names>F.</given-names></name>
<name><surname>Pisani</surname><given-names>V.</given-names></name>
<name><surname>Arcangeli</surname><given-names>F.</given-names></name>
<name><surname>Harding</surname><given-names>A.</given-names></name>
<name><surname>Singhrao</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Locus Coeruleus Dysfunction and Trigeminal Mesencephalic Nucleus Degeneration: A Cue for Periodontal Infection Mediated Damage in Alzheimer&#x02019;s Disease?</article-title><source>Int. J. Environ. Res. Public Health</source><year>2023</year><volume>20</volume><elocation-id>1007</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph20021007</pub-id><pub-id pub-id-type="pmid">36673763</pub-id></element-citation></ref><ref id="B129-medicina-59-00504"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Ning</surname><given-names>W.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Franceschi</surname><given-names>D.</given-names></name>
<name><surname>Ogbuehi</surname><given-names>A.</given-names></name>
<name><surname>Lethaus</surname><given-names>B.</given-names></name>
<name><surname>Savkovic</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Identifying crosstalk genetic biomarkers linking a neurodegenerative disease, Parkinson&#x02019;s disease, and periodontitis using integrated bioinformatics analyses</article-title><source>Front. Aging Neurosci.</source><year>2022</year><volume>14</volume><fpage>1032401</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.1032401</pub-id><pub-id pub-id-type="pmid">36545026</pub-id></element-citation></ref><ref id="B130-medicina-59-00504"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pareto</surname><given-names>D.</given-names></name>
<name><surname>Sastre-Garriga</surname><given-names>J.</given-names></name>
<name><surname>Auger</surname><given-names>C.</given-names></name>
<name><surname>Vives-Gilabert</surname><given-names>Y.</given-names></name>
<name><surname>Delgado</surname><given-names>J.</given-names></name>
<name><surname>Tintore</surname><given-names>M.</given-names></name>
<name><surname>Montalban</surname><given-names>X.</given-names></name>
<name><surname>Rovira</surname><given-names>A.</given-names></name>
</person-group><article-title>Juxtacortical lesions and cortical thinning in multiple sclerosis</article-title><source>Am. J. Neuroradiol.</source><year>2015</year><volume>36</volume><fpage>2270</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A4485</pub-id><pub-id pub-id-type="pmid">26450537</pub-id></element-citation></ref><ref id="B131-medicina-59-00504"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubchenko</surname><given-names>E.</given-names></name>
<name><surname>Ivanov</surname><given-names>A.</given-names></name>
<name><surname>Spirina</surname><given-names>N.</given-names></name>
<name><surname>Smirnova</surname><given-names>N.</given-names></name>
<name><surname>Melnikov</surname><given-names>M.</given-names></name>
<name><surname>Boyko</surname><given-names>A.</given-names></name>
<name><surname>Gusev</surname><given-names>E.</given-names></name>
<name><surname>Kubatiev</surname><given-names>A.</given-names></name>
</person-group><article-title>Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis</article-title><source>Brain Sci.</source><year>2020</year><volume>10</volume><elocation-id>637</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci10090637</pub-id><pub-id pub-id-type="pmid">32947812</pub-id></element-citation></ref><ref id="B132-medicina-59-00504"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spirina</surname><given-names>N.N.</given-names></name>
<name><surname>Spirin</surname><given-names>N.N.</given-names></name>
<name><surname>Kiseleva</surname><given-names>E.V.</given-names></name>
<name><surname>Dubchenko</surname><given-names>E.A.</given-names></name>
<name><surname>Boyko</surname><given-names>A.N.</given-names></name>
</person-group><article-title>Homocysteine and markers of endothelial dysfunction in multiple sclerosis</article-title><source>Zhurnal Nevrol. I Psikhiatrii Im SS Korsakova</source><year>2021</year><volume>121</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.17116/jnevro202112107290</pub-id></element-citation></ref><ref id="B133-medicina-59-00504"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>S.R.</given-names></name>
<name><surname>Flauzino</surname><given-names>T.</given-names></name>
<name><surname>Sabino</surname><given-names>B.S.</given-names></name>
<name><surname>Kallaur</surname><given-names>A.P.</given-names></name>
<name><surname>Alfieri</surname><given-names>D.F.</given-names></name>
<name><surname>Kaimen-Maciel</surname><given-names>D.R.</given-names></name>
<name><surname>Morimoto</surname><given-names>H.K.</given-names></name>
<name><surname>Delicato de Almeida</surname><given-names>E.R.</given-names></name>
<name><surname>Lozovoy</surname><given-names>M.A.B.</given-names></name>
<name><surname>Vissoci Reiche</surname><given-names>E.M.</given-names></name>
<etal/>
</person-group><article-title>Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis</article-title><source>Metab. Brain Dis.</source><year>2018</year><volume>33</volume><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1007/s11011-018-0224-4</pub-id><pub-id pub-id-type="pmid">29797117</pub-id></element-citation></ref><ref id="B134-medicina-59-00504"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaufmann</surname><given-names>M.</given-names></name>
<name><surname>Schaupp</surname><given-names>A.L.</given-names></name>
<name><surname>Sun</surname><given-names>R.</given-names></name>
<name><surname>Coscia</surname><given-names>F.</given-names></name>
<name><surname>Dendrou</surname><given-names>C.A.</given-names></name>
<name><surname>Cortes</surname><given-names>A.</given-names></name>
<name><surname>Kaur</surname><given-names>G.</given-names></name>
<name><surname>Evans</surname><given-names>H.G.</given-names></name>
<name><surname>Mollbrink</surname><given-names>A.</given-names></name>
<name><surname>Navarro</surname><given-names>H.F.</given-names></name>
<etal/>
</person-group><article-title>Identification of early neurodegenerative pathways in progressive multiple sclerosis</article-title><source>Nat. Neurosci.</source><year>2022</year><volume>25</volume><fpage>944</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1038/s41593-022-01097-3</pub-id><pub-id pub-id-type="pmid">35726057</pub-id></element-citation></ref><ref id="B135-medicina-59-00504"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayer</surname><given-names>A.U.</given-names></name>
<name><surname>Keller</surname><given-names>O.N.</given-names></name>
<name><surname>Ferrari</surname><given-names>F.</given-names></name>
<name><surname>Maag</surname><given-names>K.-P.</given-names></name>
</person-group><article-title>Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease</article-title><source>Am. J. Ophthalmol.</source><year>2002</year><volume>133</volume><fpage>135</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(01)01196-5</pub-id><pub-id pub-id-type="pmid">11755850</pub-id></element-citation></ref><ref id="B136-medicina-59-00504"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Mylopoulos</surname><given-names>N.</given-names></name>
<name><surname>Boura</surname><given-names>P.</given-names></name>
<name><surname>Bessas</surname><given-names>C.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
<name><surname>Venizelos</surname><given-names>J.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
</person-group><article-title>Relationship between <italic toggle="yes">Helicobacter pylori</italic> infection and glaucoma</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(00)00598-4</pub-id><pub-id pub-id-type="pmid">11237916</pub-id></element-citation></ref><ref id="B137-medicina-59-00504"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Chatzopoulos</surname><given-names>D.</given-names></name>
</person-group><article-title>Primary open-angle glaucoma: Pathophysiology and treatment</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>1311</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17179-1</pub-id><pub-id pub-id-type="pmid">15474127</pub-id></element-citation></ref><ref id="B138-medicina-59-00504"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Bargiotas</surname><given-names>P.</given-names></name>
<name><surname>Liatsos</surname><given-names>C.</given-names></name>
<name><surname>Shiva Srivastava</surname><given-names>D.</given-names></name>
<name><surname>Zavos</surname><given-names>C.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Association between active <italic toggle="yes">Helicobacter pylori</italic> infection and glaucoma: A systematic review and meta-analysis</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>894</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8060894</pub-id><pub-id pub-id-type="pmid">32545826</pub-id></element-citation></ref><ref id="B139-medicina-59-00504"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>B.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Liang</surname><given-names>M.</given-names></name>
<name><surname>Evans</surname><given-names>A.C.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Dao</surname><given-names>C.</given-names></name>
</person-group><article-title>Reduced Cortical Thickness in Primary Open-Angle Glaucoma and Its Relationship to the Retinal Nerve Fiber Layer Thickness</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e73208</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0073208</pub-id><pub-id pub-id-type="pmid">24019910</pub-id></element-citation></ref><ref id="B140-medicina-59-00504"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Barwick</surname><given-names>S.R.</given-names></name>
<name><surname>Yoon</surname><given-names>Y.</given-names></name>
<name><surname>Smith</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Effect of long-term chronic hyperhomocysteinemia on retinal structure and function in the cystathionine-&#x003b2;-synthase mutant mouse</article-title><source>Exp. Eye Res.</source><year>2022</year><volume>214</volume><fpage>108894</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2021.108894</pub-id><pub-id pub-id-type="pmid">34906600</pub-id></element-citation></ref><ref id="B141-medicina-59-00504"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Navneet</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Mysona</surname><given-names>B.</given-names></name>
<name><surname>Barwick</surname><given-names>S.</given-names></name>
<name><surname>Ammal Kaidery</surname><given-names>N.</given-names></name>
<name><surname>Kaddour-Djebbar</surname><given-names>S.A.I.</given-names></name>
<name><surname>Bollag</surname><given-names>W.B.</given-names></name>
<name><surname>Thomas</surname><given-names>B.</given-names></name>
</person-group><article-title>Hyperhomocysteinemia-induced death of retinal ganglion cells: The role of M&#x000fc;ller glial cells and NRF2</article-title><source>Redox. Biol.</source><year>2019</year><volume>24</volume><fpage>101199</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2019.101199</pub-id><pub-id pub-id-type="pmid">31026769</pub-id></element-citation></ref><ref id="B142-medicina-59-00504"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papaefthymiou</surname><given-names>A.</given-names></name>
<name><surname>Doulberis</surname><given-names>M.</given-names></name>
<name><surname>Katsinelos</surname><given-names>P.</given-names></name>
<name><surname>Liatsos</surname><given-names>C.</given-names></name>
<name><surname>Polyzos</surname><given-names>S.A.</given-names></name>
<name><surname>Kotronis</surname><given-names>G.</given-names></name>
<name><surname>Papanikolaou</surname><given-names>K.</given-names></name>
<name><surname>Kountouras</surname><given-names>J.</given-names></name>
</person-group><article-title>Impact of nitric oxide&#x02019;s bidirectional role on glaucoma: Focus on <italic toggle="yes">Helicobacter pylori</italic>-related nitrosative stress</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2020</year><volume>1465</volume><fpage>10</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/nyas.14253</pub-id><pub-id pub-id-type="pmid">31642532</pub-id></element-citation></ref><ref id="B143-medicina-59-00504"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>J&#x000fc;nemann</surname><given-names>A.</given-names></name>
<name><surname>Rejdak</surname><given-names>R.</given-names></name>
<name><surname>Hohberger</surname><given-names>B.</given-names></name>
</person-group><article-title>Stellenwert vom Homocystein beim Glaukom</article-title><source>Klin. Monbl. Augenheilkd.</source><year>2018</year><volume>235</volume><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1055/s-0044-101621</pub-id><pub-id pub-id-type="pmid">29448287</pub-id></element-citation></ref><ref id="B144-medicina-59-00504"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>T&#x000fc;rkc&#x000fc;</surname><given-names>F.M.</given-names></name>
<name><surname>K&#x000f6;z</surname><given-names>&#x000d6;.G.</given-names></name>
<name><surname>Yarang&#x000fc;meli</surname><given-names>A.</given-names></name>
<name><surname>&#x000d6;ner</surname><given-names>V.</given-names></name>
<name><surname>Kural</surname><given-names>G.</given-names></name>
</person-group><article-title>Plasma homocysteine, folic acid, and vitamin B12 levels in patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and normotensive glaucoma</article-title><source>Medicina</source><year>2013</year><volume>49</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.3390/medicina49050034</pub-id><pub-id pub-id-type="pmid">24247916</pub-id></element-citation></ref><ref id="B145-medicina-59-00504"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
<name><surname>Xing</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
</person-group><article-title>B vitamins and prevention of cognitive decline and incident dementia: A systematic review and meta-analysis</article-title><source>Nutr. Rev.</source><year>2022</year><volume>80</volume><fpage>931</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1093/nutrit/nuab057</pub-id><pub-id pub-id-type="pmid">34432056</pub-id></element-citation></ref><ref id="B146-medicina-59-00504"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Besteher</surname><given-names>B.</given-names></name>
<name><surname>Wagner</surname><given-names>G.</given-names></name>
<name><surname>Koch</surname><given-names>K.</given-names></name>
<name><surname>Schachtzabel</surname><given-names>C.</given-names></name>
<name><surname>Reichenbach</surname><given-names>J.R.</given-names></name>
<name><surname>Schl&#x000f6;sser</surname><given-names>R.</given-names></name>
<name><surname>Sauer</surname><given-names>H.</given-names></name>
<name><surname>Schultz</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Pronounced prefronto-temporal cortical thinning in schizophrenia: Neuroanatomical correlate of suicidal behavior?</article-title><source>Schizophr. Res.</source><year>2016</year><volume>176</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2016.08.010</pub-id><pub-id pub-id-type="pmid">27567290</pub-id></element-citation></ref><ref id="B147-medicina-59-00504"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhilyaeva</surname><given-names>T.v.</given-names></name>
<name><surname>Piatoikina</surname><given-names>A.S.</given-names></name>
<name><surname>Bavrina</surname><given-names>A.P.</given-names></name>
<name><surname>Kostinal</surname><given-names>O.v.</given-names></name>
<name><surname>Zhukova</surname><given-names>E.S.</given-names></name>
<name><surname>Shcherbatyuk</surname><given-names>T.G.</given-names></name>
<name><surname>Blagonravova</surname><given-names>A.S.</given-names></name>
<name><surname>Dubinina</surname><given-names>E.E.</given-names></name>
<name><surname>Mazo</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances?</article-title><source>Schizophr. Res. Treatment</source><year>2021</year><volume>2021</volume><fpage>7721760</fpage><pub-id pub-id-type="doi">10.1155/2021/7721760</pub-id><pub-id pub-id-type="pmid">34707909</pub-id></element-citation></ref><ref id="B148-medicina-59-00504"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rasool</surname><given-names>M.</given-names></name>
<name><surname>Malik</surname><given-names>A.</given-names></name>
<name><surname>Saleem</surname><given-names>S.</given-names></name>
<name><surname>Ashraf</surname><given-names>M.A.B.</given-names></name>
<name><surname>Khan</surname><given-names>A.Q.</given-names></name>
<name><surname>Waquar</surname><given-names>S.</given-names></name>
<name><surname>Zahid</surname><given-names>A.</given-names></name>
<name><surname>Shaheen</surname><given-names>S.</given-names></name>
<name><surname>Abu-Elmagd</surname><given-names>M.</given-names></name>
<name><surname>Gauthaman</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Role of Oxidative Stress and the Identification of Biomarkers Associated With Thyroid Dysfunction in Schizophrenics</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><fpage>6946287</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.646287</pub-id></element-citation></ref><ref id="B149-medicina-59-00504"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kleine</surname><given-names>A.D.</given-names></name>
<name><surname>Reuss</surname><given-names>B.</given-names></name>
</person-group><article-title>Interactions of Antibodies to the Gram-Negative Gastric Bacterium <italic toggle="yes">Helicobacter pylori</italic> with the Synaptic Calcium Sensor Synaptotagmin 5, Correlate to Impaired Vesicle Recycling in SiMa Human Neuroblastoma Cells</article-title><source>J. Mol. Neurosci.</source><year>2021</year><volume>71</volume><fpage>481</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1007/s12031-020-01670-0</pub-id><pub-id pub-id-type="pmid">32860155</pub-id></element-citation></ref><ref id="B150-medicina-59-00504"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yilmaz</surname><given-names>Y.</given-names></name>
<name><surname>Gul</surname><given-names>C.B.</given-names></name>
<name><surname>Arabul</surname><given-names>M.</given-names></name>
<name><surname>Eren</surname><given-names>M.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Helicobacter pylori</italic>: A role in schizophrenia?</article-title><source>Med. Sci. Monit.</source><year>2008</year><volume>14</volume><fpage>HY13-6</fpage><pub-id pub-id-type="pmid">18591925</pub-id></element-citation></ref><ref id="B151-medicina-59-00504"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<name><surname>Annalisa</surname><given-names>T.</given-names></name>
<name><surname>Teresa</surname><given-names>D.R.</given-names></name>
<name><surname>Giovanna</surname><given-names>D.</given-names></name>
<name><surname>Ianiro</surname><given-names>G.</given-names></name>
<name><surname>Franco</surname><given-names>S.</given-names></name>
<name><surname>Gerardi</surname><given-names>V.</given-names></name>
<name><surname>Tesori</surname><given-names>V.</given-names></name>
<name><surname>Lopetuso</surname><given-names>L.R.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>A.</given-names></name>
</person-group><article-title>Role of <italic toggle="yes">Helicobacter pylori</italic> infection on nutrition and metabolism</article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>12809</fpage><lpage>12817</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i36.12809</pub-id><pub-id pub-id-type="pmid">25278679</pub-id></element-citation></ref><ref id="B152-medicina-59-00504"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moser</surname><given-names>P.</given-names></name>
</person-group><article-title>Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia</article-title><source>Eur. Neuropsychopharmacol.</source><year>2014</year><volume>24</volume><fpage>774</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2013.11.004</pub-id><pub-id pub-id-type="pmid">24332891</pub-id></element-citation></ref><ref id="B153-medicina-59-00504"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>H.E.</given-names></name>
<name><surname>Roffman</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Vitamin supplementation in the treatment of schizophrenia</article-title><source>CNS Drugs</source><year>2014</year><volume>28</volume><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1007/s40263-014-0172-4</pub-id><pub-id pub-id-type="pmid">24846474</pub-id></element-citation></ref><ref id="B154-medicina-59-00504"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>C.</given-names></name>
<name><surname>Weng</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Vitamins and <italic toggle="yes">Helicobacter pylori</italic>: An Updated Comprehensive Meta-Analysis and Systematic Review</article-title><source>Front. Nutr.</source><year>2022</year><volume>8</volume><fpage>781333</fpage><pub-id pub-id-type="doi">10.3389/fnut.2021.781333</pub-id><pub-id pub-id-type="pmid">35118105</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-59-00504-f001"><label>Figure 1</label><caption><p>Schematic illustration of proposed pathophysiological pathways connecting <italic toggle="yes">Helicobacter pylori</italic> infection and neurodegeneration. AD, Alzheimer&#x02019;s disease; &#x003b1;-syn, &#x003b1;-synuclein; BBB, blood&#x02013;brain barrier; Gal-3, Galectin-3; <italic toggle="yes">H. pylori, Helicobacter pylori</italic>; HHcy, hyperhomocysteinemia; OMV, outer membrane vehicles; TNF&#x003b1;, tumor necrosis factor-&#x003b1;.</p></caption><graphic xlink:href="medicina-59-00504-g001" position="float"/></fig><fig position="float" id="medicina-59-00504-f002"><label>Figure 2</label><caption><p>Schematic illustration of proposed pathophysiological mechanism (s) connecting <italic toggle="yes">Helicobacter pylori</italic> infection and neurodegeneration through the hyperhomocysteinemia pathway. CCV, cardio-cerebrovascular disorders; <italic toggle="yes">H. pylori</italic>, <italic toggle="yes">Helicobacter pylori</italic>.</p></caption><graphic xlink:href="medicina-59-00504-g002" position="float"/></fig></floats-group></article>